MedTech World Magazine Issue 3 | North America 2026

Editorial

For MedTech, 2026 will be about moving ahead collectively toward collaborative objectives to establish a global investment-based ecosystem for health-related innovation and growth. The MedTech North America Summit will take place in Florida on May 11-13. It will coincide with the release of the current edition of “MedTech World” magazine, which focuses on continued advances in the industry.

Florida is rapidly becoming a centre of importance for Life Sciences and Digital Health. It is expanding again in terms of the number of hospitals, research venues, and investors aligning with global Healthcare priorities to make their solutions scalable and to enable more efficient patient access to healthcare.

One of the most important themes in healthcare innovation is that it has recently shifted toward implementation grounded in experience and outcomes rather than theoretical concepts. A clear example of this shift can be seen in today’s many medtech entrepreneurs who share their own healthcare stories as they develop product ideas to meet specific patient needs, particularly in areas such as preventive care and remote patient monitoring. This represents a fundamental change in how medical device manufacturers think about innovation; they now focus on creating innovations that better serve patients.

In addition to these important points about patients and the people who care for them, these papers discuss topics such as interoperability and the utilisation of artificial intelligence in the diagnostic process. Organisational and operational infrastructure, such as electronic health records and other digital tools, will also be examined, as will how healthcare’s growth will continue rapidly, now with a focus on alignment, governance, and scalability across various markets and components of the healthcare system.

Finally, regulation continues to play an important role. The growing presence of health technology solutions worldwide has created a need for coherent, adaptable regulations, and stakeholders are encouraging greater collaboration to achieve sustainable progress.

Dr Dylan Attard continues to play a key role in shaping this ecosystem. From a single event in Malta to a growing global summit series, his work has helped build a trusted platform for industry exchange and collaboration, supported by a strong editorial and production team.

In essence, this edition reflects a sector defined by momentum, accountability, and a sharper focus on outcomes that matter most.

Katy Micallef, Editor MedTech World Magazine

2026年开启了医疗科技领域的新篇章，为构建 一个协作、投资驱动、国际化的医疗健康创新生 态系统铺平了道路。四月，各利益相关方将聚焦 佛罗里达州，11日至13日，医疗科技北美峰会将 在此举行。与此同时，本期《MedTech世界杂志》 将作为今年峰会的配套出版物发行，随着医疗科 技的持续增长，这些出版物将共同捕捉该领域 的创新成果。

佛罗里达州不仅仅是一个举办地，它正逐步成为 美洲生命科学、数字健康及临床进步的重要中心。 凭借其不断扩展的医院网络、研究机构和投资 群体，该州反映了当今全球医疗健康的诸多优势， 从可扩展性到系统整体集成，再到改善患者服务。

本期打造了一致的主题：医疗健康创新由亲身经 历、运营限制和可衡量的结果所塑造,正日益扎 根于实际应用。焦点已从理论上技术能做什么， 转向实际上它能交付什么。

关键主题是，医疗健康领域创始人的个人经历如 何持续启发创造新的医疗科技产品，他们常常借 鉴自己的经历，为医疗健康系统中特定需求领域 开发解决方案，特别是在预防保健和远程患者监 测方面。这表明医疗设备行业正朝着以患者为导 向而创新的趋势。

同样，其他方面也强调了重症监护这一挑战性环 境，其中临床决策与患者及其家人的个人经历常 常交织在一起。这些凸显了所有医疗健康服务创 新背后的人性因素。

除了患者和护理人员的重要观点外，这些论文还 讨论了诸如互操作性和人工智能在诊断过程中 的应用，审视机构和运营基础，电子健康记录和 其他数字工具，以及医疗健康如何继续快速增长， 同时聚焦于跨市场和医疗健康系统组件的协调、 治理和可扩展性。

最后，监管继续发挥着重要作用。全球健康技术 解决方案的日益增多，催生了对连贯、适应性强 的监管需求，利益相关方正鼓励加强合作以实现 可持续发展。

Dylan Attard博士在塑造这一生态系统方面继续 发挥着关键作用。从马耳他的单一活动到不断壮 大的全球峰会系列，他帮助建立了一个受信赖的 行业交流与合作平台，并得到了强大的编辑和生 产团队的支持。

随着行业齐聚佛罗里达，讨论将超越峰会本身， 影响投资、政策以及医疗健康服务的未来。

从从本质上讲，本期内容所展现的医疗科技行业 正呈现出强劲的发展动力、高度的责任意识，以 及对关键成果更为精准的聚焦。

Contributors

42

Cover Story

Inside MedTech’s golden age

医疗科技行业的黄金时代

GREG MADDEN, Managing Partner at SV Health Investors, speaks about what led him to the medical technology investment sector and why he believes the industry is entering a transformative era.

12

Rewiring medtech capital: Why institutional readiness now defines success

重塑医疗科技资本格局： 为何机构的早期准备将决 定成败

DR GEORGE SYRMALIS, CEO at Bioscience Equity Partners S.A., on whether early stage medical device companies in Europe and N. America are prepared for the realities of institutional capital, and cross-border funding.

18

The day that changed lives and started a Medtech journey

里程碑：改变人生、开启 医疗科技之旅

KEN NELSON, partner and founder of Nelson Jennings Ventures, explains what drew him into the world of medical technology.

22

Investing in the future of medicine, one breakthrough at a time

以一次次的突破，投资医 学的未来

Cleveland Clinic Innovations is turning caregivers’ bold ideas into life-changing solutions. JD FRIEDLAND plays a key role in this strategy, leading a team that transforms discoveries from hospital labs into thriving startups, licensed technologies, and strategic partnerships - all with one goal: improving patient care worldwide.

27

Turning a personal ordeal into a cybersecurity mission

将个人磨难转化为网络安 全使命

Up close and personal with CHRISTIAN ESPINOSA, Founder and CEO of Blue Goat Cyber and and bestselling author of ‘The Smartest Person in the Room: The Root Cause and New Solution for Cybersecurity’.

32

Breathing

innovation: How Synchrony Medical is transforming at-home respiratory care

呼吸的创新：Synchrony Medical为家庭呼吸护理 带来的变革

Synchrony Medical CEO ANAT SHANI discusses the inspiration behind LibAirty, a breakthrough digital airway clearance system, and how patient-centric innovation is reshaping chronic lung disease management.

37

Navigating legal strategy and growth in life sciences startups

生命科学初创企业的法律 政策与成长之路

JOHN SHIRE, Co-Chair, Health Care & Life Sciences at Cozen O’Connor, outlines the critical legal considerations shaping success in the health care and life sciences sector.

50

Closing the gap: How Vivasure Medical reinvented vascular closure

弥合差距：Vivasure Medical如何革新血管闭 合技术

Vivasure Medical’s CEO ANDREW GLASS on what sparked the creation of Vivasure Medical.

54

Wound up for change: Adtec Healthcare’s plasma-powered revolution in infection care

为了变革蓄势待 发：Adtec Healthcare在 感染护理领域的等离子体 技术革命

We speak to MARY MCGOVERN, CEO of Adtec Healthcare, on her journey from plasma technology engineering to medtech leadership.

58

Next generation surgery: How Medtronic is advancing robotics worldwide

下一代手术：美敦力如何 在全球推进机器人手术

RAJIT KAMAL, Vice President and General Manager of Robotic Surgical Technologies at Medtronic on what it takes to drive the global roll-out of next-generation robotic-assisted surgery.

62

The American Heart Association: A catalyst for innovation

美国心脏协会：创新的催 化剂

THE AMERICAN HEART ASSOCIATION’s Center for Health Technology & Innovation outlines its mission to bridge science and technology.

66

Florida’s Life-Sciences moment: Turning momentum into market leadership

佛罗里达生命科学：将发 展势头转化为市场领导力

President & CEO of BioFlorida, MARK GLICKMAN, discusses where innovation truly begins,the risks of fragmentation, and how Florida can transition from an emerging player to a global destination for life sciences.

A

note from the

CEO and co-founder

It is a pleasure to welcome you to this edition of MedTech World Magazine, released alongside the MedTech North America Summit, which takes place in Florida from 11 to 13 May.

Florida has become a familiar place for me. I first visited three years ago, and what started as a straightforward trip has turned into a location I keep coming back to, both professionally and personally.

Bringing this edition here carries clear symbolism. Often regarded as the land of opportunity, North America has become a meeting point for ambition, investment, and innovation. In the context of medical technology, Florida is positioning itself as a hub where clinical expertise, entrepreneurial drive, and capital converge, increasingly shaping the MedTech landscape in North America.

For MedTech World, this summit marks an important evolution. While we have traditionally co-hosted focused, one-day gatherings across multiple markets, this event represents our first flagship multi-day summit in North America. It brings together a more structured platform for dialogue, collaboration, and deal-making across the ecosystem.

This progression reflects both growth and intent. As our global footprint expands, so does the responsibility to create consistent, high-impact environments for the communities we serve. Florida offers the right conditions for this next step, with strong infrastructure and a growing appetite for healthcare innovation.

On a personal level, I feel increasingly aligned with the state’s trajectory. The idea of spending more time in Florida feels like a natural extension of MedTech World’s direction, as we continue to connect ecosystems and enable progress in healthcare innovation.

This summit is a statement of intent. It reinforces our commitment to North America, to supporting companies exploring expansion, and to bridging international innovation with the US healthcare system. Florida is emerging as a gateway for these ambitions.

Within this magazine, you will find perspectives from across MedTech and HealthTech, reflecting the collaborative spirit that defines our work.

I look forward to welcoming many of you to MedTech North America for what promises to be a defining moment in our journey.

Dr. Dylan Attard MD, MRCSI, MEnt. CEO AND CO-FOUNDER, MEDTECH WORLD

Dylan Attard 致辞

非常荣幸地欢迎您阅读本期 MedTech World Magazine，本期杂志将与5月11日至13日在佛罗 里达州举行的MedTech北美峰会同期发布。

佛罗里达对我而言已不再陌生。三年前的首次 到访原本只是一次简单的旅行，后来却逐渐变成 了一个让我流连忘返的地方，无论是出于工作还 是个人原因。

选择在此地发布本期杂志具有鲜明的象征意义。

北美常被视为机遇圣地，如今已成为雄心、投资 与创新的交汇点。在医疗科技领域，佛罗里达正 将自己定位为一个汇聚临床专业知识、创业精神 和资本市场的枢纽，不断塑造着北美的医疗科 技格局。

对于 MedTech World 而言，本次峰会标志着重 大发展。尽管我们曾在多个市场联合举办过单日 的聚焦活动，但本次活动是我们在北美首次举 办的旗舰级多日峰会。它搭建了一个更为结构化 的平台，供整个生态系统的参与者进行对话、合 作与交易。

这一进展既体现了我们的成长，也彰显了我们的 决心。随着我们的国际影响力不断扩大，为所服 务的社区创造持续的高影响力环境也成为了我 们的责任。佛罗里达为此提供了理想的条件，这 里拥有强大的基础设施和对医疗健康创新日益 增长的需求。

在个人层面，我越来越认同该州的发展轨迹。在 佛罗里达的岁月就像是《MedTech World》发展 方向的自然延伸，我们继续连接着各个生态系 统，推动着医疗健康创新的进步。

本次峰会是一次声明。它重申了我们对北美的承 诺，对支持探索扩张公司的承诺，以及对将国际 创新与美国医疗体系相结合的承诺。佛罗里达正 成为这些雄心勃勃企业的门户。

在本期杂志中，您将看到来自医疗科技和健康科 技领域的多方观点，让协作精神绽放光彩。

我期待着在MedTech北美峰会上欢迎各位的到 来，这必将是我们旅程中的一个决定性时刻。

Dr Dylan Attard, MD, MRCSI, MEnt MedTech World 联合创始人兼首席执行官

Rewiring

medtech capital:

Why institutional readiness now defines success

Duncan Barry speaks to DR GEORGE SYRMALIS, CEO at Bioscience Equity Partners S.A., on whether early stage medical device companies in Europe and N. America are prepared for the realities of institutional capital, and cross-border funding.

Early-stage medical device companies in Europe and North America are, candidly, underprepared for the realities of institutional capital, particularly from the Gulf. The gap is not scientific. Founders are typically rigorous in developing their technology and clinical pathways. The real deficiency is institutional.

Sovereign capital operates within a framework that is both more demanding and more strategic than traditional venture capital. It requires governance structures, documentation standards, and offering materials that meet multi-jurisdictional regulatory expectations. More importantly, it requires a clear articulation of the full capital trajectory, not just the current funding round. Too often, companies arrive prepared for a conventional venture conversation, when what is required is something closer to pre-IPO readiness.

This mismatch is emerging at a time when the traditional funding pathway for medical devices is beginning to fracture. US venture capital, long the backbone of early-stage funding, has become increasingly selective. Devices are difficult to reconcile with fund models built around ten-year cycles and software-like return profiles. Regulatory timelines are long, capital requirements are high, and reimbursement pathways remain complex.

There is a generational shift underway... from passive financial investment to active participation in healthcare transformation

Strategic corporates, meanwhile, are still active but have shifted toward acquisition rather than development. They prefer to buy de-risked assets rather than fund them through uncertainty. The result is a widening funding gap at the early and mid stages, one that is increasingly being filled by international capital with longer time horizons and more strategic mandates.

Cross-border funding, however, introduces its own complexities. Valuation remains the most persistent source of friction. US venture firms tend to rely on comparable exits and financial multiples, while sovereign investors often assess strategic value -including market access, technology transfer, and alignment with national healthcare priorities. Reconciling these perspectives requires a level of structuring sophistication that many companies and advisors simply do not possess.

Governance presents another challenge, particularly around board composition and decision-making rights. Simpler equity structures are increasingly preferred, both for clarity and for compatibility with frameworks such as Islamic finance. Complexity at this stage often leads to misalignment later.

Amid this evolving landscape, the strategic intent of Gulf capital is still widely misunderstood. There is a generational shift underway: from passive financial investment to active participation in healthcare transformation. These institutions are not operating on five-year return cycles; they are building national capability, investing in infrastructure, and positioning their economies for a post-hydrocarbon future.

Yet, many Western founders fail to engage with this shift. Those who do, who can articulate how their technology aligns with national priorities and contributes to broader healthcare ecosystems, enter a fundamentally different conversation. They are not simply raising capital; they are forming strategic partnerships.

重塑医疗科技资本格局：

为何机构的早期准备将 决定成败

Duncan Barry就欧洲和北美早期医疗 设备公司是否准备好应对机构资本及跨 境融资的现实问题，采访了Bioscience Equity Partners S.A.的首席执行官 George Syrmalis博士。

坦率地说，对于机构资本的现状，尤其是来自海湾地 区的资本，欧洲和北美的早期医疗设备公司准备不足。 这一差距并非在科技层面。创始人通常在开发技术和 临床路径方面严谨细致。真正的不足在于机构层面。

主权资本是在一个比传统风险投资更为严苛且更具战 略性的框架内运作。它要求治理结构、文档标准，符 合多辖区监管的材料。更重要的是，它需要清晰阐述 完整的资本路径，而不仅仅是当前的融资轮次。很多 时候，公司准备的是传统风险投资，而实际需要的却 是接近上市前（pre-IPO）的准备。

这种不匹配出现在传统医疗设备融资路径开始瓦解之 际。长期以来，一直是早期阶段融资支柱的美国风险 投资，已变得越来越挑剔。医疗设备行业难与十年周 期和类似软件回报模式的资金模型相协调。监管时间 漫长，资本需求高昂，偿付路径复杂。

与此同时，战略企业仍然活跃，但已转向收购而非开 发。它们更倾向于购买已降低风险的资产，而非在不 确定性中为其提供资金。结果是在早期和中期阶段出 现了不断扩大的资金缺口，这一缺口正越来越多地由 具有更长投资期限和更战略任务的国际资本填补。 然而，跨境融资也带来了自身的复杂性。估值仍是冲 突的来源。美国风险投资公司倾向于依赖退出机制和 财务增长，而主权投资者则常常评估战略价值——包 括市场准入、技术转让以及与国家医疗保健优先事项 的契合度。调和这些观点需要许多公司和顾问所不具 备的成熟结构。

治理是另一个挑战，特别是在董事会构成和决策权方 面。为了清晰明了，也为了与伊斯兰金融等框架兼容， 大家越来越倾向于采用更简单的股权结构。该阶段过 于复杂往往会导致后期的错位。

A similar dynamic is unfolding in Asia. Institutional capital from Singapore, Japan, and China is becoming increasingly influential in global medtech. Still, many founders treat these investors opportunistically rather than strategically. This

trade sale, or licensing model - and work backward to design a connected funding pathway. Investors should be aligned across stages, and relationships should be continuous rather than transactional. The companies that adopt this approach raise capital more efficiently and with far less disruption.

One of the most opportunities lies in point-of-care emerging markets...

is a mistake. These capital sources are motivated not only by financial returns, but by access to technology, manufacturing expertise, and regulatory insight. Companies motivations are structuring more resilient and strategically aligned funding syndicates.

At the core of many funding fundamental issue: the absence of a defined end-state. Too many companies raise capital reactively, moving from round to round without a coherent long-term plan. This creates negotiating leverage, and leaves businesses vulnerable

A

well-structured capital strategy should begin with the destination - whether

In medtech, the primary risks are scientific and regulatory. These require patience, specialised knowledge, and capital structures that can accommodate uncertainty over longer timelines.

Alternative models are gaining traction. Institutional capital with longer horizons, strategic alignment, and continuous advisory involvement is proving better suited to the sector.

In terms of sector focus, international capital is gravitating toward areas where technological innovation intersects with chronic disease burden, i.e. cardiovascular devices, surgical robotics, and advanced diagnostics. Yet one of the most overlooked opportunities lies in point-ofcare diagnostics for emerging markets, where unmet need and strategic relevance are both significant.

Ultimately, the defining characteristic of successful medical device companies is no longer just scientific excellence. It is institutional maturity. And NASDAQ, although it remains the canonical exit, the path is becoming longer and more capital-intensive.

在这一不断演变的格局中，海湾资本的战略意图仍被广 泛误解。当前正在发生一场代际转变：从被动金融投资转 向积极参与医疗保健转型。这些机构并非按照五年回报 周期运作；它们正在为建设国家，投资基础设施，为其经 济在后碳氢化合物时代的定位做准备。

然而，许多西方创始人未能理解这一转变。那些能够阐述 其技术如何与国家优先事项相契合，并如何为更广泛的 医疗保健生态系统做出贡献的创始人，则进入了一个截 然不同的境界。他们不仅仅是在筹集资金；他们是在建立 战略合作伙伴关系。

类似的动态也在亚洲上演。来自新加坡、日本和中国的 机构资本在全球医疗科技领域的影响力日益增强。然 而，许多创始人仍将这些投资者视为机会主义者，而非战 略伙伴，这是错误的。这些资金来源不仅受财务回报的 驱动，还受获取技术、学习专长和监管洞察的驱动。理 解这些动机的公司正在构建更具韧性和战略一致性的融 资集团。

许多融资挑战的核心在于一个更根本的问题：缺乏明确 的终局状态。太多公司被动地筹集资金，从一轮融资到另 一轮融资，没有连贯的长期计划。这导致效率低下，削弱了 谈判筹码，并使企业容易受到市场周期的影响。

一个结构良好的资本策略应从目标开始——无论是公开上 市、贸易出售还是许可模式——然后逆向设计一个连贯的 融资路径。投资者应在各阶段保持一致，关系应是连续 的而非交易性的。采用这种方法的公司能够更高效地筹 集资金，且受到的干扰更少。

在医疗科技领域，主要风险是科学和监管方面的。这些 需要耐心、专业知识和能够适应长时间不确定性的资本 结构。

替代模式正逐渐获得认可。具有更长投资期限、战略一 致性和持续参与咨询的机构资本更适合该行业。

在行业关注点方面，国际资本正倾向于技术创新与慢性 病负担相交集的领域，即心血管设备、手术机器人和先进 诊断技术。然而，一个最被忽视的机会在新兴市场的即时 检验诊断（point-of-care diagnostics），那里需求和战 略相关性都很显著。

最终，成功的医疗设备公司的决定性特征不再仅仅是 卓越的科学技术，而是机构成熟度。尽管纳斯达克仍然 是典型的退出途径，但这条路正变得越来越长且资本 密集。

The day that changed lives and started a Medtech journey

At times, a single moment can change the course of many lives.

For KEN NELSON, partner and founder of Nelson Jennings Ventures, one such incident became the catalyst that drew him into the world of medical technology. Speaking with Duncan Barry, Nelson reflects on the moment that reshaped his path and the drive behind his commitment to the Medtech sector.

Believe it or not, the catalyst that ultimately led Ken Nelson into the MedTech industry was the tragedy of September 11, 2001, in New York City.

At the time, Nelson was working in finance for a software startup in Atlanta, watching the events unfold in real time on the internet. The moment prompted deep reflection about the kind of impact he wanted his career to have.

“This is when I decided I wanted to be more involved in making a difference in the world,” he recalls. “I wanted to be part of something that could improve, and even save lives.”

As he began exploring what that next step might look like, Nelson became fascinated by implantable pacemakers and defibrillators: technologies capable of regulating heart rhythms or delivering life-saving shocks to restore a normal heartbeat. The idea that a device could intervene so directly to save a life sparked a strong passion for the cardiac rhythm management (CRM) field.

Nelson created a five-year plan to move into sales and leadership roles at one of the major cardiac device companies Medtronic, St Jude Medical (now Abbott), or Guidant (now Boston Scientific).

Eventually, he convinced Guidant to bring him on board in Atlanta as a senior sales and pricing analyst. Over the next five years he was promoted no less than four times, transitioning into sales and later sales leadership, remaining in that role even after Guidant was acquired by Boston Scientific.

Today, Nelson channels that experience into his work at Nelson Jennings Ventures. The firm focuses on building a comprehensive cardiac start-up innovation ecosystem while supporting a select group of disruptive companies along the way. Its work revolves around consulting and investing in cardiac medical devices, digital health, and AI-enabled startups, particularly those connected to the global accelerator MedTech Innovator.

Key opportunities exist in continuous hemodynamic monitoring, remote therapeutic management, AI-driven prediction of cardiac decompensation, and closed-loop drug and device therapies.

Nelson says two experiences significantly shaped his approach to evaluating earlystage healthcare startups. The first was his time at Guidant, where he learned the importance of leadership, mentorship, and company culture. “The people building the organisation and the culture they create are the lifeblood of a startup,” he says, noting that passion, potential, and perseverance are often the strongest indicators of future success.

The second influence came in 2019 when, as CCO at Bardy Diagnostics (later acquired by Hillrom, now part of Baxter), the company was selected for the MedTech Innovator accelerator programme. Nelson later became a judge at the organisation’s global pitch events, gaining insight into how venture capital firms and strategic investors evaluate founders and emerging technologies.

Startups operating at the intersection of cardiology, neuroscience, artificial intelligence, and wearable technology excite Nelson most. Companies developing AIpowered tools to detect and predict heart disease, as well as wearable therapeutic devices that challenge the standard of care in arrhythmia treatment, represent some of the most promising innovations in the field.

Nelson Jennings Ventures also benefits from Nelson’s unique perspective across several pioneering companies in cardiac digital health and remote patient monitoring.

里程碑：改变人生、开启

医疗科技之旅

有时，一个瞬间就能改变许多人的人生轨 迹。对于Nelson Jennings Ventures的合伙 人兼创始人Ken Nelson来说，有件事促使他 踏入了医疗科技世界。在与Duncan Barry 的交谈中，Nelson回顾了那个重塑他人生道 路的时刻，以及他投身于Medtech领域的动 力所在。

信不信由你，引领Ken Nelson进入医疗科技行业的，是 2001年9月11日发生在纽约市的悲剧。

当时，Nelson正在亚特兰大一家软件初创公司从事金融 工作，他通过互联网实时目睹了事件的发生。那一刻促使 他深刻反思自己职业生涯的影响。

“就在那时，我决定要更多地参与到能够为世界带来改变 的事业中去，”他回忆道，“我希望成为能够改善生活，挽 救生命事业的一部分。”

在开始探索下一步方向时，Nelson对植入式心脏起搏器 和除颤器产生了浓厚兴趣：这些技术能够调节心律或提 供救命电击以恢复正常心跳。一个设备能够如此直接地 介入挽救生命，这激发了他对心脏节律管理（CRM）领域 的强烈热情。

Nelson制定了一个五年计划，旨在进入Medtronic、St Jude Medical（现属Abbott）或Guidant（现属Boston Scientific）等主要心脏设备公司的销售和领导岗位。

最终，他在亚特兰大被Guidant聘请担任高级销售与定价 分析师。在接下来的五年里，他至少获得了四次晋升，从 销售岗位逐渐晋升至销售领导岗位，即使在Guidant被 Boston Scientific收购后，他仍继续担任该职务。

如今，Nelson将这段经历融入到了他在Nelson Jennings Ventures的工作中。该公司专注于构建一个全 面的心脏初创企业创新生态系统，同时在这一过程中支 持一批具有颠覆性创新的公司。其工作围绕心脏医疗设 备、数字健康和AI驱动的初创企业的咨询与投资展开，特 别是那些在全球促进医疗科技创新的企业。

Nelson表示，有两段经历塑造了他评估早期医疗健康初 创企业的方法。第一段是在Guidant的经历，他从中认识

Over the years he has held senior commercial leadership roles at BioTelemetry (as Global VP of Sales), iRhythm Technologies (as VP of Sales and Marketing), and Bardy Diagnostics (as Chief Commercial Officer). These organisations represent three of the top four market-share leaders in cardiac digital health and remote monitoring, particularly in the development of wearable cardiac patch monitors.

Nelson says he brings practical experience to mentoring and advising early-stage founders. Nelson focuses on three defining qualities when it comes to founders: passion, potential, and perseverance. One of the most common mistakes when pitching is failing to communicate genuine passion for the problem being solved. Founders also sometimes overlook critical business fundamentals.

Several areas in Medtech remain underserved by both capital and technological development. One of the most significant is heart failure and cardio-renal metabolic disease. Around seven million people in the United States live with heart failure, a number that continues to grow alongside rising hospitalisation and readmission costs.

“Key opportunities exist in continuous hemodynamic monitoring, remote therapeutic management, AI-driven prediction of cardiac decompensation, and closed-loop drug and device therapies,” he says.

Nelson also points to iRhythm Technologies as an example of how startups can evolve significantly from their original thesis. During his time there, he helped build the team that launched the Zio Patch, a wearable cardiac monitoring device designed as a more patient-friendly alternative to the traditional 24-48 hour wired Holter monitor. While the company initially focused on hardware innovation, it soon realized the real value lay in the data platform and diagnostic services built around the device. The company pivoted toward a fullservice model combining wearable monitoring with AI-assisted ECG analysis and physician reporting, turning data and diagnostic insights into its true competitive advantage.

到了领导力、导师指导和公司文化的重要性。“组织 构建者以及他们创造的文化是初创企业的生命线，” 他指出激情、潜力和毅力在未来往往是成功的关键 指标。

第二个影响来自2019年，当时作为Bardy

Diagnostics（后被Hillrom收购，现为Baxter的一部 分）的首席商务官，该公司入选了医疗科技创新孵化 项目。Nelson后来成为该组织全球推介活动的评委， 深入了解了风险投资公司和战略投资者如何评估创 始人和新兴技术。

Nelson对那些处于心脏病学、神经科学、人工智能 和可穿戴技术交叉领域的初创企业最感兴趣。开发 人工智能工具来检测和预测心脏病，以及开发可穿戴 治疗设备以挑战心律失常治疗标准的企业，代表了该 领域最有前景的创新。

Nelson Jennings Ventures还受益于Nelson在心脏 数字健康和远程患者监测领域几家先锋企业的独特 视角。多年来，他曾在BioTelemetry担任全球销售副 总裁、在iRhythm Technologies担任销售与市场副 总裁，在Bardy Diagnostics担任首席商务官。这些 机构代表了心脏数字健康和远程监测领域市场份额 前四家中的三家，特别是在可穿戴心脏贴片监测器 的开发领域。

Nelson表示，他在指导和建议早期创始人时获得了 实践经验。在评估创始人时，他关注三个决定性品质： 激情、潜力和毅力。推介时的常见错误是未能传达对 待解决问题的真正激情。创始人有时也会忽视关键 的商业基础。

医疗科技领域有几点在资本和技术发展方面仍然服 务不足。其中最为显著的是心力衰竭和心肾代谢疾 病。美国约有七百万人患有心力衰竭，这一数字随着 住院和再入院成本的上升而持续增长。

“在持续血液动力学监测、远程治疗管理、人工智能 驱动的心脏失代偿预测以及闭环药物和设备治疗方 面存在重大机遇，”他说。

Nelson还以iRhythm Technologies为例，阐述了初 创企业如何从最初的设想中演变。在他任职期间，他 帮助组建推出了Zio Patch团队，这是一款可穿戴心 脏监测设备，旨在作为比传统24-48小时有线Holter 监测仪更便捷的替代品。虽然公司最初专注于硬件 创新，但很快意识到真正的价值在于围绕该设备构 建的数据平台和诊断服务。公司转向了一种结合可 穿戴监测、人工智能辅助心电图分析和医生报告的 全服务模式，将数据和诊断结果转化为其真正的竞 争优势。

Investing in the future of medicine, one breakthrough at a time

At the forefront of healthcare innovation, Cleveland Clinic Innovations is turning caregivers’ bold ideas into life-changing solutions. As Executive Director of Investments and Ventures at Cleveland Clinic Innovations, JD FRIEDLAND plays a key role in this strategy, leading a team that transforms discoveries from hospital labs into thriving startups, licensed technologies, and strategic partnerships - all with one goal: improving patient care worldwide. Duncan Barry investigates.

Since Cleveland Clinic Innovations was founded in 2000, its mission has been to take ideas sparked by medical professionals and turn them into products, patents, companies, and beyond. Friedland oversees the Ventures team, which identifies emerging, transformational innovations originating inside and outside Cleveland Clinic. These ideas often become partnerships with companies, where Cleveland Clinic licenses technology and receives an ownership stake. Innovations also creates startup companies,

We aim to build a portfolio of solutions that can create a multiplier effect through the capital we deploy.

licensing intellectual property to these ventures, and invests in these startups and outside companies that form strategic collaborations with Cleveland Clinic.

Friedland’s team supports each venture’s success, often serving as board members, observers or advisors. They collaborate closely with management teams to raise external capital, provide coaching, navigate challenges, and drive clinical advancement, commercial adoption, and highvalue exits. “We aim to build a portfolio of solutions that

can create a multiplier effect through the capital we deploy,” Friedland explains. The Innovations model generates value in multiple ways: advancing patient care, often establishing Cleveland Clinic as a customer, co-developing solutions, licensing technology, and investing in companies.

Friedland’s journey into healthcare innovation began on Wall Street as an equity research analyst covering biotechnology and medical device stocks. He later worked as an investment banker, helping companies raise capital and explore M&A alternatives, and later joined Henry Schein, a healthcare solutions company. Before coming to Cleveland Clinic, he worked at a private equity firm focused on advancing highpotential healthcare opportunities. A friend at Cleveland Clinic Innovations encouraged him to consider relocating from New York, and Friedland saw it as a chance to work at one of the leading organisations in healthcare. Collaborating with clinical leaders like Drs. Andre Machado, Frank Papay, Samir Kapadia, and Jose Navia sealed the decision. “I’m now about to celebrate my five-year anniversary, and it’s gone by in a flash,” he reflects.

Collaboration with clinical inventors and researchers is central to Innovations’ work. Engagement partners guide caregivers through submitting invention disclosures, the first step in advancing an idea into licensable intellectual property. From ideation,patenting, prototyping, preclinical and clinical data collection, to licensing, specialised teams support each stage while maintaining close contact with inventors. Some inventors remain deeply involved, like Dr. Machado, who continues to shape technologies related to deep brain stimulation for stroke. Cleveland Clinic’s intellectual property policy allows inventors to share in potential licensing economics, creating a recruitment and retention advantage for clinicians and researchers to focus on their core jobs, while working with Innovations to turn their ideas into transformational healthcare solutions.

Artificial intelligence is increasingly a “force multiplier” in clinical innovation. Cleveland Clinic has been on the forefront of utilizing AI to support its mission of being the best place to receive care and a top place to work in healthcare.. One example is Ambience’s AI platform, which documents patient appointments and generates medical notes for provider approval. the platform also creates customised after-visit summaries for patients and families, reducing administrative burden and enriching patient experience.

Friedland notes that strategic collaborations in AI are expanding rapidly, and Cleveland Clinic is focused on bringing unique value to the table, with its robust data sets, deep clinical insights and expertise. “These assets allow us to co-develop solutions that

以一次次的突 破，投资医学的 未来

作为医疗保健创新的前 沿，克利夫兰诊所创新 中心（Cleveland Clinic

Innovations）正将医护人 员的大胆构想转化为改变生 活的解决方案。作为克利夫 兰诊所创新中心投资与风 险部门执行董事，JD·弗里 德兰（JD FRIEDLAND）在 这一战略中扮演着关键角 色，他带领团队将医院实验 室的研究成果转化为蓬勃发 展的初创企业、技术授权以 及战略合作伙伴关系——所 有这一切都只有一个目标： 改善全球患者的护理。邓肯· 巴里（Duncan Barry）对此 进行了调查。

自2000年成立以来，克利夫兰诊所 创新中心的使命一直是将医疗专业 人员激发的创意转化为产品、专利、 企业等等。弗里德兰负责的风险团 队正在验证克利夫兰诊所全方位的 变革性创新。这些创意常常会与公 司形成合作伙伴关系，克利夫兰诊 所授权技术并获得股权。创新中心 还可创立初创公司，向这些企业授 权知识产权，并投资于这些初创公 司以及与克利夫兰诊所形成战略合 作的外部公司。

弗里德兰的团队不遗余力地支持 着这些企业，常常担任董事会成员、 观察员或顾问。他们与管理团队紧 密合作，筹集外部资金，提供指导，

应对挑战，并推动临床进展、商业 应用和高价值通道。“我们的目标 是通过我们部署的资本，构建一个 能够产生倍增效应的解决方案组 合，”弗里德兰解释道。创新模式通 过多种方式创造价值：推进患者护 理，把克利夫兰诊所作为客户，共 同开发解决方案，授权技术，以及 投资公司。

弗里德兰的医疗保健创新之旅始于 华尔街，作为一名股权研究分析师， 他全面了解生物技术和医疗设备的 股票。后来，他成为一名投资银行 家，帮助公司筹集资金并探索并购 替代方案，随后加入了医疗解决方 案公司Henry Schein。在来到克利 夫兰诊所之前，他在一家专注于推 进高潜力医疗保健机会的私募股权 公司工作。克利夫兰诊所创新中心 的一位朋友鼓励他从纽约迁往此处， 弗里德兰视此为在领先医疗保健组 织工作的机会。与Andre Machado 博士、Frank Papay博士、Samir Kapadia博士和Jose Navia博士 等临床先驱的合作，坚定了他的决 定。“我即将庆祝在这里工作的五周 年，时间过得飞快，”他回忆道。

与临床发明人员和研究人员的合作 是创新中心工作的核心。参与指导 医护人员提交发明是将创意推进为 可授权知识产权的第一步。从创意 构思、专利申请、原型制作、临床 前和临床过程中的数据收集，到授 权，专业团队在每个阶段都提供着 支持，同时与发明者保持紧密联系。

一些发明人员仍深度参与研究，如 Machado博士，他继续研究着与中 风深部脑刺激相关的技术。克利夫 兰诊所的知识产权政策允许发明人 员分享潜在的授权收益，招募和保 留优势使临床医生和研究人员可以 专注于核心工作，同时与创新中心 的合作将他们的创意转化为变革性 的医疗保健解决方案。

人工智能正日益成为临床创新的“ 力量倍增器”。克利夫兰诊所一直 利用人工智能使该工作场所成为最

The work we do at Cleveland Clinic Innovations really speaks to all of Cleveland Clinic’s values - serve with heart, succeed as one team, and shape the future.

are not only cutting-edge but also deeply aligned with the needs of patients and providers,” Friedland says.

Balancing scientific rigor with business considerations is seamless at Cleveland Clinic because of its ecosystem of expert clinicians and researchers. Innovations provides intellectual property management, strategic licensing, and startup incubation support, while Cleveland Clinic researchers and clinicians offer real-world scientific insights and resources for clinical validation. “I don’t have to be the smartest bioethicist, interventional cardiologist, and orthopedic surgeon in the world. We have all those experts at Cleveland Clinic, and they help us,” Friedland says.

The most rewarding aspect of medical technology commercialisation, according to Friedland, is witnessing the impact on patients. For example, portfolio companies like Enspire DBS Therapy help stroke patients restore arm motor function through deep brain stimulation. Seeing patient outcomes firsthand reinforces the “why” behind Innovations’ work: identifying transformational opportunities that expand access, deliver better care, and enhance experiences for patients and caregivers.

MediView, a Cleveland Clinic portfolio company that uses augmented reality to aid in surgical navigation, is an example of a long-term successful collaboration. [1] The technology behind MediView’s XR90 started with Cleveland Clinic intellectual property and enables proceduralists to visualise a patient’s anatomy in 3D augmented reality during minimally invasive procedures. Initially applied in interventional radiology, the technology now spans multiple specialties. Proximity to the company within Innovations’ incubator space fosters frequent interactions and maintains strong relationships, while investors and partners work together closely to advance the technology.

Maintaining resilience and long-term focus is achieved through structured planning. Annual retreats help align the team on strategic objectives. These meetings examine five-year goals, mediumterm plans over the next 18 months to two years, and short-term annual objectives, ensuring both vision and execution remain

on track. Under the leadership of Chief of Innovations Dr. Geoff Vince, the team has increased invention-to-license translations, attracted new inventors, and expanded investments in portfolio companies through datadriven processes and measurable objectives.

At its core, Cleveland Clinic Innovations exemplifies a comprehensive approach to healthcare advancement. By combining clinical insight, strategic investment, licensing expertise, and entrepreneurial rigor, the organisation transforms breakthrough ideas into tangible solutions that improve patient care around the world. Cleveland Clinic Innovations’ work demonstrates how one institution can leverage its expertise, partnerships, and capital to shape the future of medicine - one breakthrough at a time.

“The work we do at Cleveland Clinic Innovations really speaks to all of Cleveland Clinic’s values - serve with heart, succeed as one team, and shape the future”, says Friedland. “Ultimately, we’re identifying transformational opportunities that are going to expand access, deliver better care, create a better experience for patients and caregivers, and bring the best possible care to the greatest number of people. That’s incredibly rewarding.

佳护理场所和医疗保健行业的前沿。 如Ambience的人工智能平台，该平 台记录患者预约并生成供医生批准 的医疗记录。该平台还为患者和家 属创建定制的就诊后总结，减轻了 行政负担并丰富了患者的体验。

弗里德兰指出，人工智能领域的战 略合作正在迅速扩大，克利夫兰诊 所专注于凭借其强大的数据集、深 入的临床洞察和专业知识带来独特 价值。“这些资产使我们能够共同 开发不仅前沿而且与患者和医护人 员需求深度契合的解决方案，”弗 里德兰说。

由于拥有专家临床医生和研究人员 的生态系统，克利夫兰诊所能够无 缝平衡科学严谨性与商业考量。创 新中心提供知识产权管理、战略授 权和初创企业孵化支持，而克利夫 兰诊所的研究人员和临床医生则提 供科学实践和资源用于临床验证。“

我不必成为世界上最聪明的生物伦 理学家、介入心脏病学家和骨科外 科医生。我们克利夫兰诊所拥有所 有这些专家，他们可以帮助我们，” 弗里德兰说。

据弗里德兰称，医疗技术商业化最 令人满意的是见证对患者的影响。 例如，像Enspire DBS疗法这样的投 资组合公司，通过深部脑刺激帮助 中风患者恢复手臂运动功能。亲眼 看到患者预后的情况强化了创新中 心工作的意义：识别变革性机会，扩 大服务范围，提供更好的护理，并 改善患者和医护人员的体验。

MediView是克利夫兰诊所投资组 合中的一家利用增强现实辅助手术 导航的公司，是长期合作的成功典 范。[1]MediView的XR90技术始于 克利夫兰诊所的知识产权，使手术 医生能够在微创手术过程中以3D增 强现实方式看到患者解剖结构。该 技术最初应用于介入放射学，现已扩 展至多个专科。与创新中心孵化器 内的公司增进联系促进了频繁互动 并巩固了关系，同时投资者和合作 伙伴可以紧密合作来推进技术。

我们旨在通过我们 部署的资本，构建一 个能够产生倍增效 应的解决方案组合。

通过结构化规划收获韧性和长期关 注。年度务虚会有助于团队就战略 目标达成一致。这些会议审视五年 长期目标、未来18个月至两年的中 期计划以及短期年度目标，确保愿 景和具体执行保持一致。在创新中 心首席官Geoff Vince博士的领导下， 团队通过数据驱动流程和可衡量目 标增加了发明到授权的转化，吸引了 新的发明者，并扩大了对投资组合 公司的投资。

本质上，克利夫兰诊所创新中心展 示了医疗保健进步的综合方法。通 过结合临床洞察、战略投资和授权 专业知识，再加上创业的严谨性，该 组织将突破性创意转化为改善全球 患者护理的切实解决方案。克利夫 兰诊所创新中心的工作展示了单一 机构如何利用其专业知识、合作伙 伴关系和资本来塑造医学的未来， 实现一次次的突破。

“我们在克利夫兰诊所创新中心所做 的工作真正体现了克利夫兰诊所的 所有价值观——用心服务、团队合 作以及塑造未来，”弗里德兰说。“ 我们的终极目标是识别变革性机会， 这些机会将扩大服务范围，提供更 好的护理，为患者和医护人员创造 更好的体验，并将最好的护理带给 更多人。这非常鼓舞人心。”

Turning a personal ordeal into a cybersecurity mission

In early 2022, CHRISTIAN ESPINOSA had six blood clots in his left leg, and it nearly killed him. It forced him into a headspace he had never been in before. He was not thinking about career goals or business goals. He was thinking: “Am I going to make it?” Medtech speaks with the Founder and CEO of Blue Goat Cyber and best-selling author of ‘The Smartest Person in the Room: The Root Cause and New Solution for Cybersecurity’.

Words by Duncan Barry

“A portable Doppler ultrasound device played a key role in getting me diagnosed quickly enough to survive. That is when “security” stopped being a technical term. It became a trust issue,” Christian started to recount.

“When you are looking at something that might save your life, you realise fast that reliability is everything. Accuracy matters. Uptime matters. Integrity matters. You need that technology to work the way it was intended, when it is supposed to, in a real clinical environment.

“That experience rewired how I define cybersecurity in healthcare. If someone can disrupt a device, alter its performance, tamper with its output, or take it offline, the impact is not just data loss or downtime.

The goal isn’t to ‘pass cybersecurity’. It is to defend the device in the field.

Cybersecurity becomes patient safety. That is the origin of Blue Goat Cyber. I did not start it because I wanted to write more reports. I started it because I realized medical devices deserve the same seriousness we apply to safety engineering, and security is part of that.”

How did your personal experience transform cybersecurity from a technical discipline into something deeply human?

“That health scare made everything human, fast. You stop thinking in frameworks and start thinking in consequences. It made me ask a simple question that a lot of teams do not ask early enough: what happens to a patient if this device is wrong, unavailable, or manipulated?

“The gap I saw in MedTech is that cybersecurity often lives in the wrong place on the timeline. Too many companies treat it as a late-stage documentation exercise right before submission. Then it turns into panic. Engineering is stuck defending design decisions that were never made with security assumptions in mind. Regulatory is trying to tell a coherent story using evidence that was not created to support that story.

“Blue Goat Cyber exists to close that gap by helping manufacturers build cybersecurity into the product from day one and maintain it through the lifecycle. That means aligning engineering reality with what regulators expect to see: secure design practices, security risk management, credible testing evidence, and a plan to monitor and respond after launch.”

Climbing the Cybersecurity mountain

It goes without saying after having read the first part of this interview that Blue Goat Cyber reflects the founder’s personal philosophy as much as the company’s mission. An avid mountain climber, he says the “goat” symbolises the patience, balance and discipline needed to navigate steep terrain, much like medical device cybersecurity and regulatory requirements.

“The climb is real,” he explains. “You don’t get through it by sprinting and hoping. You get through it by taking the right route and keeping your footing.”

The “blue” represents the calm mindset needed in high-stakes situations: slowing down, thinking clearly and making defensible decisions, an approach the firm applies to cybersecurity strategy.

Security that works in theory but fails in a real hospital environment isn’t security.

Blue Goat Cyber supported the Malta MedTech World Startup Pitch Competition, an initiative aimed at encouraging secure innovation among emerging medical technology companies.

The firm believes start-up competitions play a crucial role in shaping early design habits.

“If founders understand from the beginning that cybersecurity is part of product strategy, it becomes part of design and quality,” he says. “If it comes later, it turns into a scramble, and in MedTech that leads to delays, rework and trust issues.”

When evaluating startups, the company looks for several signals: whether products are designed for real hospital environments, how responsibly connectivity is handled, and whether security claims are backed by evidence such as threat modeling and software component inventories. Long-term life-cycle thinking, including monitoring and vulnerability response, is another key factor.

The cost of ignoring security

Treating cybersecurity as an afterthought can have serious consequences. Beyond regulatory complications, it can create patient safety risks and operational disruption.

“Late cybersecurity fixes create inconsistencies between the architecture, risk analysis and testing story,” he explains. “Regulators notice those gaps.”

Companies also risk post-market problems if they lack systems to monitor vulnerabilities and respond quickly once devices are deployed.

For Blue Goat Cyber, the solution is integrating cybersecurity from the earliest design stage through the entire product life-cycle.

“Early is when you still have choices,” he says. Early planning allows manufacturers to build secure architectures, define trust boundaries and design update mechanisms that work in real healthcare environments.

With connected medical devices deployed worldwide, cybersecurity has become a global responsibility.

“Devices ship everywhere and hospitals share expectations,” he says. “Security that works in theory but fails in a real hospital environment isn’t security.”

As connectivity and artificial intelligence expand in healthcare technology, manufacturers must adopt disciplined approaches to access control, monitoring, secure updates and lifecycle risk management.

“The goal isn’t to ‘pass cybersecurity’. It is to defend the device in the field.”

将个人磨难转 化为网络安全 使命

2022年初，CHRISTIAN ESPINOSA的左腿出现了 六个血凝块，这几乎要了他 的命。这迫使他进入了一 种前所未有的心境。他不 再思考职业目标或商业目 标，而是在想：“我能挺过去 吗？”Medtech采访了Blue Goat Cyber的创始人兼首 席执行官，同时也是畅销书 《房间里最聪明的人：网络安 全的根源与新解决方案》的 作者。

DUNCAN BARRY：

“便携式多普勒超声设备在使我得到 及时诊断以保住性命方面发挥了关 键作用。那一刻，‘安全’不再是一 个技术术语，它变成了一个信任问 题，”Christian开始讲述道。

“当你面对可能挽救你生命的东西时， 你会很快意识到可靠性就是一切。 准确性至关重要。正常运行时间至 关重要。完整性至关重要。你需要 这项技术在真实的临床环境中按预 期方式工作。

“那次经历彻底改变了我对医疗领域 网络安全的定义。如果有人能干扰 设备、改变其性能、篡改其输出或 使其离线，那就不仅仅是数据丢失 或停机了。网络安全就是要保障患 者的安全。这就是Blue Goat Cyber 成立的初衷。我创立它不是因为我 想写更多报告，而是因为我意识到

医疗设备应该与安全工程同等重要， 安全是不可或缺的一部分。”

你的个人经历是如何将网络安 全从一门技术学科转变为具有 深刻人文意义的领域的？ “那次健康危机迅速让一切关注点都 聚焦于人性化。你不会再从框架的 角度思考，而是从后果的角度思考。

这让我提出了一个很多团队没有尽 早提出的问题：如果这个设备出错、 无法使用或被篡改，患者会怎样？

“我在医疗科技领域看到的差距是， 网络安全在时间线上往往处于错 误的位置。太多公司将其放在了提 交前的最后阶段。这就会带来恐慌。

工程师们不得不为该设计决策进行 辩护，而该决策并不是基于安全假 设做出的。监管机构则试图用并非 为支持该叙述而创建的证据来讲述 一个连贯的叙述。

“Blue Goat Cyber的存 在就是为了缩小这一差 距，帮助制造商从第一 天起就将网络安全融入 产品，并在整个生命周 期中保持下去。这意味 着要将现实工程与监管 机构的期望保持一致： 安全设计、安全风险管 理、可信的测试证据以 及发布后的监控和响应 计划。”

攀登网络安全的高山

无需多言，读完这篇采 访的第一部分后，你就 会明白Blue Goat Cyber 既反映了创始人的个人 哲学，也体现了公司的 使命。作为一名狂热的 登山者，他说：“山羊” 象征着在陡峭地形中保 持方向所需的耐心、平 衡和纪律，就像医疗设 备的网络安全和监管要 求一样。

“攀登是脚踏实地的，”他解释道。“

你不能通过冲刺和碰运气来完成它。 你要通过选择正确的路线并保持脚 步稳定来完成它。”

“蓝色”代表着在高风险情况下所需 的冷静心态：放慢脚步、清晰思考并 做出有据可依的决策，这是该公司 应用于网络安全战略的方法。

Blue Goat Cyber支持了马耳他医疗 科技世界初创企业推介竞赛，这是 一项旨在鼓励新兴医疗科技公司进 行安全创新的倡议。

该公司认为，初创企业竞赛在塑造 早期设计习惯方面发挥着至关重要 的作用。

“如果创始人从一开始就明白网络安 全是产品战略的一部分，那么它就 会成为整体设计和保障质量的一部 分，”他说。“如果做得晚，就会变得

一团糟，而在医疗科技领域，这会导 致工期延误、返工和信任问题。”

在评估初创企业时，该公司会关注 几个信号：产品是否为真实的医院 环境而设计、是否负责任地处理连 接性，以及安全声明是否不利于建 模和软件组件。另一个关键因素是 长期生命周期思维，包括监控和漏 洞响应。

忽视安全的代价

将网络安全做为事后考虑可能会带 来严重后果。除了增加监管复杂性 以外，它还可能造成患者安全风险 和运营中断。

“后期的网络安全修复会在架构、风 险分析和测试叙述之间造成不一 致，”他解释道。“监管机构会注意 到这些差距。”

如果公司缺乏在设备部署后监控漏 洞并快速响应的系统，还会面临上 市后的问题。

对于Blue Goat Cyber来说，解决方 案是从最早的设计阶段到整个产品 生命周期都融入网络安全。

“早期是你还有选择的时候，”他说。

早期规划允许制造商构建安全的架 构、定义信任边界并设计在真实医 疗环境中有效的更新机制。

随着连接医疗设备在全球范围内 的部署，网络安全已成为一项全球 责任。

“当设备运往世界各地时，医院有着 共同的期望，”他说。“理论上可行 但在真实医院环境中失败的安全不 是真正的安全。”

随着连接性和人工智能在医疗技术 中的扩展，制造商必须采用严格的 方法来进行访问控制、监控、安全 更新和生命周期风险管理。

“目标不仅仅是通过网络安全检验。 而是要能在现场保护设备。”

For many patients, the impact of effective airway clearance goes beyond better clinical outcomes, it provides freedom to live life to the fullest, without being sidelined by their condition.

Breathing innovation:

How Synchrony Medical is transforming at-home respiratory care

In this MedTech World feature, Synchrony Medical CEO ANAT SHANI discusses with Duncan Barry the inspiration behind LibAirty, a breakthrough digital airway clearance system, and how patient-centric innovation is reshaping chronic lung disease management.

For Anat Shani, the path into healthcare innovation was clear from the outset. With a background in biomedical engineering, Shani entered the MedTech sector driven by a desire to combine technical expertise with real-world impact. Early experience in research and development roles, followed by an MBA focused on innovation and entrepreneurship, laid the foundation for her to lead a MedTech startup from ideation into its current early commercial growth phase.

Synchrony Medical was founded during the early days of the COVID-19 pandemic in collaboration with leading clinicians from Sheba Medical Center, including Prof. Ori Efrati, Dr Moshe Ashkenazi and Gil Sokol. While the global health crisis accelerated the urgency for remote care solutions, it also exposed long-standing gaps in respiratory treatment - particularly for patients managing chronic lung diseases at home. The founding team set out to address a critical

challenge: enabling patients with chronic respiratory disease to independently manage their condition through effective airway clearance therapy.

Airway clearance is a cornerstone of treatment for conditions such as bronchiectasis and cystic fibrosis. The process involves removing mucus from the lungs, reducing infection risks, improving breathing, and slowing disease progression. However, some existing methods require significant training or clinical supervision, making consistent, effective treatment difficult to maintain outside healthcare settings.

“Airway clearance can be achieved through a variety of techniques that aim to loosen, move and expel sticky mucus from the lungs. The challenge is that airway clearance devices need to be both effective enough to deliver clinically meaningful results and practical enough for patients to self-administer independently at home on a daily basis,” Shani explained.

Shani walked Medtech World Magazine through how LibAirty works, and what inspired its creation.

“Synchrony’s solution, LibAirty, represents a significant step forward. The FDA-cleared system combines app-guided breathing exercises with targeted chest compressions delivered through an inflatable vest. Inspired by the clinically proven technique of Autogenic Drainage, LibAirty translates complex, therapist-led methods into a user-friendly, at-home solution.

“During therapy sessions, patients are guided through controlled breathing patterns via a mobile app, while the vest delivers synchronized compressions. This coordinated approach aims to mobilize mucus from the smaller, hardest to clear, airways, facilitating thorough lung clearance during each session. By acting as a ‘digital therapist,’ the system empowers patients to perform high-quality therapy independently on a daily basis.”

The development of LibAirty was deeply shaped by close collaboration with clinicians and patients alike. Insights from respiratory specialists ensured that the device’s design was grounded in physiological principles, while patient feedback helped refine its usability and comfort, two factors essential for long-term adherence.

Clinical data has been promising. Studies conducted at Sheba Medical Center and the Medical University of South Carolina showed that patients using LibAirty were able to clear twice the amount of mucus compared to traditional vest-based therapies, while also reporting higher levels of comfort and satisfaction. Since its commercial launch in the United States in late 2025,

呼吸的创

新：Synchrony

Medical为家 庭呼吸护理带 来的变革

在MedTech World的专

题报道中，Synchrony

Medical首席执行官ANAT SHANI与DUNCAN BARRY 探讨了突破性数字气道清 理系统LibAirty背后的灵感， 以及以患者为中心的创新手 段如何开辟了慢性肺病管 理的新纪元。

对Anat Shani而言，投身医疗科技 创新的道路从一开始就十分明确。

拥有生物医学工程背景的Shani，怀 着将技术专长与现实世界相结合的 愿望，进入了医疗科技领域。早期 在研发岗位上的经验积累，加上专 注于创新与创业的MBA学习经历， 为她领导医疗科技初创公司从创意 构思走向商业发展奠定了基础。

Synchrony Medical成立于 COVID-19疫情初期，随后便与谢 巴医疗中心的顶尖临床医生展 开了合作，其中包括Ori Efrati教 授、Moshe Ashkenazi博士和Gil Sokol。全球健康危机加速了远程 护理解决方案的紧迫性，同时也暴 露了呼吸治疗中长期存在的空白—— 尤其是对于在家中管理慢性肺病的 患者。创始团队开始着手解决一个 关键挑战：使慢性呼吸道疾病患者 能够通过有效的气道清理疗法独立 管理自己的病情。

real-world feedback has echoed these findings, with patients reporting reduced coughing, improved sleep, and a better overall quality of life.

"For many patients, the impact of effective airway clearance goes beyond better clinical outcomes, it provides freedom to live life to the fullest, without being sidelined by their condition,” she told Medtech World.

Beyond individual outcomes, the technology also addresses broader systemic challenges. With healthcare systems under increasing pressure and a shortage of respiratory therapists, solutions like LibAirty extend expert care into the home. By empowering patients to manage their conditions independently, such innovations have the potential to reduce hospitalizations and ease long-term healthcare costs.

Looking ahead, Shani sees digital health driving a shift toward more connected, home-based care. Enabled by advanced technology, the home becomes the primary setting for treatment, supported by data-driven insights and personalized care. This approach not only improves accessibility but also enables earlier intervention and more proactive disease management.

At its core, Synchrony Medical’s vision is to redefine the standard of care for chronic respiratory diseases. By making effective, independent therapy widely accessible, the company aims to give patients greater control over their health, and, ultimately, a better quality of life.

With LibAirty already making an impact, the focus now turns to scaling its reach, as Synchrony Medical works toward transforming respiratory care for millions worldwide.

气道清理是治疗支气管扩张和囊性纤维化等病症的基石。该方法可 从肺部清除黏液，降低感染风险，改善呼吸，并减缓疾病进展。然 而，一些现有方法需要大量培训或临床监督，使得其在医疗环境之 外难以维持，不易实现有效的治疗。

“可以通过松动、移动并排出肺部黏稠黏液的技术实现气道清理。难

点在于气道清理设备必须既足够有效以提供具有临床意义的结果， 又足够实用，以便患者能够每天在家中独立使用，”Shani解释道。

Shani向Medtech World杂志介绍了LibAirty的工作原理及其创作 灵感。

“Synchrony的解决方案LibAirty取得了重大进步。这一获得FDA批 准的系统方案将呼吸练习与通过充气背心提供的针对胸部的压缩 结合在一起。受临床验证的自体引流技术的启发，LibAirty将由治 疗师主导的复杂方法转化为易于操作的家庭解决方案。

“在治疗过程中，患者通过移动应用程序控制呼吸模式，同时背心提 供同步压缩。这种协调方法旨在将黏液从小而难以清理的气道中 排出来，以实现治疗时的肺部彻底清理。通过‘数字治疗师’，该系 统使患者能够每天独立进行高质量治疗。”

LibAirty的开发深受临床医生和患者的影响。呼吸专家的见解确保 了设计基于生理学原理，而患者反馈则帮助改进了其可用性和舒适 度，这两者对长期坚持起到了关键作用。

临床数据令人鼓舞。在谢巴医疗中心和南卡罗来纳医科大学进行 的研究显示，使用LibAirty的患者清除的黏液量是传统背心疗法的 两倍，同时报告了更高的舒适度和满意度。自2025年末在美国商 业推出以来，现实反馈与这些研究发现相呼应，患者报告咳嗽减少、 睡眠改善以及整体生活质量提高。

“对许多患者而言，有效的气道清理比好的临床结果更优，它提 供了自由，让他们能够充分享受生活，不被病情所困扰，”她告诉 Medtech World。

除了对个体的疗效以外，该技术还解决了更广泛的系统性挑战。随 着医疗系统压力日益增大和呼吸治疗师短缺，像LibAirty这样的解 决方案将专家护理延伸至家庭。通过使患者能够独立管理自己的 病情，此类创新有可能减少住院次数并降低长期医疗费用。

展望未来，Shani认为数字健康正向互联互通、以家庭为基础的护 理转变。在先进技术的支持下，通过数据和个性化护理，家庭将成 为治疗的主要场所。这种方法不仅提高了普适性，还实现了更早的 干预和更积极的病情管理。

Synchrony Medical的核心愿景是重新定义慢性呼吸道疾病的治 疗标准。通过使有效、独立的疗法广泛普及，公司旨在让患者对自 己的健康拥有更大控制权，并最终提高生活质量。

目前LibAirty已经产生影响，现在的重点是扩大其覆盖范 围，Synchrony Medical致力于为全球数百万患者的呼吸护理带 来变革。

Navigating legal strategy and growth in life sciences startups

From commercialization pathways to regulatory compliance and investment trends, JOHN SHIRE, Co-Chair, Health Care & Life Sciences at Cozen O’Connor, outlines the critical legal considerations shaping success in the health care and life sciences sector.

For founders entering the life sciences space, legal strategy can be the difference between rapid growth and costly missteps. According to John, the most critical issues at launch revolve around market pathway and commercialization.

“Specifically, this means understanding how the company penetrates the market, how the company changes the market, and the exit strategy,” he explained.

Knowing the answer to this can make the difference between

a high road to nowhere, and a 10X return.

“Early-stage life sciences companies need to get several foundational issues right simultaneously: corporate structure, intellectual property ownership, regulatory strategy, and capital formation. From day one, founders should ensure IP is properly assigned, regulatory pathways are understood, and compliance obligations are baked into the business plan, not treated as an afterthought.

The regulations are currently onerous and can create unnecessary trip wires. This is an issue that we continuously monitor, and that is as much as we can do now.

“We regularly help startups balance speed to market with regulatory discipline so early missteps don’t derail later growth or investment rounds,” John told MedTech World.

Legal and regulatory implications of stablecoin use in health care

John said that the firm would caution against stablecoin use, when asked by MedTech World.

“The regulations are currently onerous and can create unnecessary trip wires. This is an issue that we continuously monitor, and that is as much as we can do now.

“Stablecoins raise complex issues at the intersection of financial regulation, fraud and abuse laws, data security, and reimbursement compliance. In health care, the risks are amplified because of heightened scrutiny around payments, inducements, and transparency,” he said.

Turning to European health care regulation, John said that it tends to be more centralized and prescriptive, particularly around data protection, medical devices, and reimbursement while the US system is more fragmented but enforcementdriven, with overlapping federal and state regimes.

Deterring how a software qualifies as a medical device under FDA rules

The analysis focuses on intended use and functionality. Software that

diagnoses, treats, or influences clinical decision-making may fall within FDA oversight, while administrative or wellness tools generally do not.

“We help clients assess risk; document intended use and determine appropriate regulatory pathways without over-regulating innovative products unnecessarily,” he explained.

We regularly help startups balance speed to market with regulatory discipline so early missteps don’t derail later growth or

investment rounds.

What are the current trends in health care and life sciences investing?

When it comes to sector investment trends, AI driven clinical outcomes that produce fewer invasive modalities, better mortality, and drive costs down are the current focus.

“Investors are focused on technologies that improve efficiency, generate realworld evidence, or integrate into existing care delivery models. There is also heightened diligence around regulatory risk, reimbursement sustainability, and data

governance. Companies that can demonstrate regulatory clarity and commercial discipline tend to attract stronger interest,” John highlighted.

Key intellectual property issues in life sciences innovation

The biggest issue is global patent prosecution since the commercialization path needs to tie directly to the footprint.

“Clear IP ownership is critical, particularly where development involves universities, research institutions, or collaborative partners. Companies also need to think beyond patents to trade secrets, data rights, and freedom-to-operate analyses. We regularly help clients align IP strategy with financing, licensing, and exit planning,” he said.

Data privacy laws meanwhile add a layer of complexity to day-to-day operations. Health care organizations operate under some of the most complex data privacy regimes in the world.

Beyond HIPAA, companies must contend with state privacy laws, cybersecurity expectations, and crossborder data issues.

But John emphasized that strong governance and contractual controls are essential to managing risk while still allowing data-driven innovation.

Legal risks in health care transactions and private equity investments

“The high-level issues hinge on commercial pathways, adoption, and market sentiment. Additional risks are triggered by compliance, oversight and industry activities having nothing to do with the target.

“Regulatory compliance, reimbursement exposure, and governance issues are top concerns. Buyers must assess not only historical compliance, but whether the business model is sustainable under evolving enforcement priorities.

“Our team regularly supports transactions by integrating regulatory diligence with deal structuring and postclose compliance planning,” he explained.

Impact of government regulations

Regulations add governance structure, time and expense to all operations across all clinical and life sciences industries.

More than 50% of all work in the space is driven by government regulations:

“The key is not just understanding the rules but anticipating how agencies will enforce them. We help clients stay ahead of regulatory shifts so they can adapt strategically, not reactively,” he concluded.

生命科学初创 企业的法律政 策与成长之路

Cozen O’Connor健康护理 与生命科学部门联合主席

JOHN SHIRE阐述了在健 康护理和生命科学领域取 得成就的关键法律因素，内 容涵盖从商业化路径到监管 合规及投资趋势。

对于进入生命科学领域的创业者而 言，法律策略可能是实现快速增长 与付出高昂代价之间的分水岭。据 John介绍，初创阶段最关键的问题 集中在市场路径与商业化方面。

“具体来说，这意味着要了解公司如 何进入市场、如何改变市场以及如 何退出市场，”他解释道。

“是否知道这些问题的答案，意味着 是走上一条不知通往何处的高速路， 还是获得10倍的回报。”

“早期生命科学公司需要同时处理好 几个基础性问题：公司架构、知识产 权归属、监管策略以及资本筹集。从 创业第一天起，创业者就应确保知 识产权得到妥善分配，监管路径清 晰明了，合规义务应被纳入商业计 划，而非事后补救。”

“我们经常帮助初创企业在追求快速 上市的同时，保持监管合规性，避 免早期失误影响后续增长或融资轮 次，”John告诉MedTech World。

医疗保健交易与私募股权投资 中的法律风险

“更高层次的问题取决于商业路径、 市场接受度及市场情绪。合规、监 督及与目标无关的行业活动可能引 发额外风险。”

“监管合规、报销风险及治理问题是 首要关注点。买家不仅需评估历史 合规情况，还需判断商业模式在不 断变化的执法关注点下是否可持

“我们的团队经常通过整合监管尽职 调查、交易结构及交易后合规规划 来支持交易，”他解释道。

政府监管的影响

监管为所有临床与生命科学行业的 运营增添了结构治理的复杂性以及 时间与成本。

该领域超过50%的工作是由政府监

“关键不仅在于理解规则，还在于预 测机构如何执行这些规则。我们帮 助客户预判监管变化，以便他们能 够进行战略性而非反应性的调整，”

Inside MedTech’s golden age

SV Health’s Greg Madden on the sector’s future

GREG MADDEN, Managing Partner at SV Health Investors, speaks to Duncan Barry about what led him to the medical technology investment sector and why he believes the industry is entering a transformative era.

Long before he was investing in medical technology companies, Greg Madden was working on the hospital floor.

The Managing Partner at Boston-based SV Health Investors first stepped into healthcare during his school years, washing dishes in a hospital cafeteria. It was not glamorous work, but it offered an early glimpse into the pace and pressures of hospital life. Later, he took a job as a security guard at the same hospital, bringing him even closer to the realities of the healthcare system.

Healthcare, he says, was never far from his life.

His mother worked as a nurse, while his father was a healthcare information systems consultant. Conversations about hospitals, patients and the evolving medical landscape were common in the Madden household.

“Healthcare found me, but it was inevitable,” he said.

Those early experiences shaped his understanding of the sector from both personal and professional perspectives, long before he entered the world of healthcare investing.

Building a career at SV Health

Madden joined SV Health Investors in 2002 at a pivotal moment for the firm. The investment group was being spun out of asset management giant Schroders plc, creating an opportunity to build a new, independent healthcare investment platform.

Starting out as an analyst, Madden quickly found himself working across a wide range of projects within the organisation.

“In the early years, I was a bit of a jack of all trades,” he said. “When you’re part of a small team building a firm from the ground up, you have the opportunity to touch almost every aspect of the business.”

Over time, he gravitated toward medical technology, an area that increasingly captured his interest because of its combination of engineering innovation, clinical impact and commercial opportunity.

Madden credits much of his professional development to the culture of mentorship at SV Health, particularly the influence of the firm’s former chief executive, Jim Garvey.

医疗科技行业 的黄金时代

SV Health投资公司的管理 合伙人Greg Madden谈行 业未来

SV Health投资公司的管 理合伙人Greg Madden与 Duncan Barry探讨了是什 么引领他进入医疗科技投资 领域，以及他为何认为该行 业正步入一个变革性的时代。

早在投资医疗科技公司之前，Greg Madden就在医院工作过。这位波 士顿SV Health投资公司的管理合 伙人，在学生时代就曾在一家医院 餐厅洗碗，并开始接触医疗行业。

这份工作虽不光鲜，却让他初步领 略了医院生活的节奏与压力。后来， 他又在同一所医院担任保安，这使 他更近距离地了解了医疗体系的实 际情况。

他说，医疗行业从未远离他的生活。

他的母亲是一名护士，父亲则是一 名医疗信息系统顾问。在Madden家 中，关于医院、患者以及不断演变的 医疗环境的讨论屡见不鲜。

“我走进了医疗行业，这也是必然的，” 他说道。

这些早期经历在他进入医疗投资领 域之前，就从个人和职业角度塑造了 他对该行业的理解。

在SV Health建立职业生涯 Madden于2002年加入SV Health 投资公司，此时正值公司发展的关 键时刻。这家投资集团正从资产管

“I was fortunate to join a new firm on the ground floor,” Madden said. “My mentor and former firm CEO, Jim Garvey, strongly believed in an apprenticeship model and the value of learning on the job. Being naturally driven and intellectually curious, I thrived in that environment.”

More than two decades later, Madden now leads SV Health’s medical technology investment strategy, guiding the firm’s approach to identifying and scaling promising companies across the sector.

A growing market opportunity

He is doing so at a time when the medical technology industry is entering a significant growth phase.

The global medical device market alone is projected to exceed $1 trillion by 2034, driven largely by demographic trends such as ageing populations and the rising incidence of chronic disease. Conditions including cardiovascular disease, diabetes and musculoskeletal disorders are becoming more prevalent as populations age, increasing demand for innovative medical solutions.

“That 6-7% annual growth is based purely on demographics,” Madden explained. “If you add digital health and the expansion of IoTdriven remote patient monitoring, you could effectively triple that market opportunity.”

The growing convergence of digital technologies, advanced sensors and data-driven healthcare tools is reshaping how care is delivered and monitored. According to Madden, these developments are creating opportunities for entirely new healthcare models.

“We’re at the start of a golden age of technology-driven healthcare transformation,” he said.

SV Health Investors has historically invested across venture capital, growth equity and buyout strategies. Over the past decade, however, the firm’s flagship funds have increasingly focused on growth and buyout investments, in all healthcare segments other than biotechnology.

“Our track record shows that by waiting until medical technology companies achieve scaling revenue, we can generate the same investment multiple roughly twice as fast while taking significantly less risk,” he said.

“The large strategic acquirers have become significantly bigger over the last 15 years,” Madden noted. “They’re now often looking at laterstage companies with established revenue streams rather than earlier-stage ventures.”

“We generally aim to invest about three to five years before the large strategic acquirers are likely to step in,” he explained.

理巨头施罗德集团（Schrodersplc） 中分拆出来，这为建立一个全新的 独立医疗投资平台提供了契机。

初入公司时，Madden担任分析师 一职，很快便参与了组织内的多个 项目。

“在早期，我算是多面手，”他说，“当 你作为团队的一员，从零开始建立一 家公司时，你几乎有机会接触到业 务的每一个方面。”

随着时间的推移，他逐渐被医疗科 技领域所吸引，这一领域因其创新 工程、临床影响力和商业机会等诸多 方面日益引起他的兴趣。

Madden将他的职业发展很大程度 上归功于SV Health的导师文化，特 别是公司前首席执行官Jim Garvey 的影响。

“我很幸运能在公司初创阶段加 入，”Madden说，“我的导师、前公 司首席执行官Jim Garvey坚信学徒 制模式和在职学习的价值。我天生 追求进取且求知欲强，适合在这种 环境中茁壮成长。”

二十多年后的今天，Madden领导 着SV Health的医疗科技投资策略， 指导公司识别并扩大该领域有前景 的公司。

不断增长的市场机遇 他正是在医疗科技行业进入显著增 长阶段时担任这一职务的。

全球医疗设备市场预计到2034年将 超过1万亿美元，这主要得益于人口 老龄化以及慢性病发病率上升等趋 势。随着人口老龄化，心血管疾病、 糖尿病和肌肉骨骼疾病等病症愈发 普遍，对创新医疗解决方案的需求 也随之增加。

“6-7%的年增长率仅仅是基于人口 统计数据，”Madden解释道，“如 果你再加上数字健康和物联网驱动

When evaluating potential investments, SV Health looks for several defining characteristics.

Strong leadership teams are a critical factor, along with large addressable markets and technologies capable of delivering measurable value within healthcare systems.

“We focus on value creation across three groups,” Madden explained. “Patients, through improved clinical outcomes; physicians, through efficiency and time savings; and payers, through demonstrable cost reductions.”

This framework reflects the complex ecosystem that shapes healthcare adoption. A new medical technology must not only demonstrate clinical effectiveness but also fit into physician workflows and deliver clear economic value.

“If you can align incentives across those stakeholders, adoption tends to follow,” Madden said.

A diamond in the rough

One example of this investment philosophy is OptiMesh, a spinal fusion technology developed by Spineology, a company in SV Health’s portfolio.

Spinal fusion is one of the most common surgical procedures in the United States, used to stabilise vertebrae and reduce pain caused by spinal instability or degenerative conditions.

When SV Health first encountered the OptiMesh technology in 2024, Madden described it as an innovative product that had not yet fully realised its commercial potential.

Despite strong potential to improve outcomes for patients while delivering benefits for physicians and healthcare payers, the technology was housed within a company that had historically struggled to scale.

“When we first encountered the technology in 2024, it was incredibly promising but sitting inside a company that hadn’t yet unlocked its potential,” Madden said.

The situation changed after Spineology appointed a new chief executive, Brian Snider, who brought renewed focus and operational discipline to the company.

It has now recorded four consecutive quarters of revenue growth above 20%, alongside the introduction of new implant technologies designed to promote bone growth and restore more natural spinal alignment.

的远程患者监测，可以将这个市场 扩大三倍。”

数字技术、先进传感器和数据驱动 的医疗工具的日益融合正在重塑医 疗服务和监测方式。据Madden称， 这些发展正在为全新的医疗模式创 造机遇。

“我们正处于技术驱动的医疗变革黄 金时代的开端，”他说。

SV Health投资公司擅长在风险投 资、成长型股权和收购策略上进行 投资。然而，在过去十年中，该公司 的旗舰基金越来越专注于成长型和 收购型投资，涵盖了除生物技术以 外的所有医疗领域。

“我们的记录显示，通过等待医疗科 技公司实现规模化营收，我们可以 在承担更低风险的同时，大致以两 倍的速度产生相同的投资，”他说。

“过去15年里，大型战略收购规模显 著扩大，”Madden指出，“他们现 在往往关注的是拥有成熟收入流的 后期公司，而非早期风险企业。”

“我们通常的目标是在大型战略收购 方介入前约三到五年进行投资，”他 解释道。

在评估潜在投资时，SV Health会寻 找几个决定性特征。

强大的领导团队是关键因素之一， 同时还要有庞大的目标市场以及能 够在医疗体系中提供可衡量价值 的技术。

“我们专注于在三个群体创造价 值，”Madden解释道，“改善了临 床效果的患者；节省了时间提高了 效率的医生；以及成本降低的医疗 机构。”

这一框架反映了被医疗系统所接受 的复杂生态系统。一项新的医疗技 术不仅必须证明其临床有效性，还 必须融入医生的工作流程，并提供 明确的经济价值。

Addressing healthcare’s biggest challenges

Looking ahead, Madden believes medical technology will play a central role in addressing some of healthcare’s most pressing structural challenges, particularly rising costs and workforce shortages.

“Medtech can help in three key ways,” he said.

“First, devices often aim for definitive interventions rather than lifelong treatments. Second, minimally invasive tools shorten procedure and recovery times. And third, the AI revolution will depend heavily on high-quality clinical data generated by medical devices and sensors.”

Technologies such as minimally invasive surgical tools, clinicalgrade wearable devices and AI-enabled healthcare platforms are already gaining traction across global healthcare systems.

“Honestly, all of them excite me,” Madden said. “Each represents a multi-billion-dollar opportunity growing at 20-30% annually.”

Virtual care and remote patient monitoring

Virtual care platforms and remote patient monitoring technologies are also expected to play an increasingly important role in healthcare delivery.

“Virtual care is fundamentally about accessibility,” Madden said.

“In the US, many people struggle to access consistent healthcare because of geography, transport limitations or work schedules. Telehealth can significantly extend the reach of the system.”

Remote patient monitoring tools offer additional benefits by allowing clinicians to track patient health outside traditional clinical settings.

Ultimately, Madden believes both venture and growth investors will play a crucial role in shaping the future of healthcare innovation.

By providing capital, strategic guidance and operational support, investors can help bring promising technologies from development to widespread adoption.

“The opportunity is enormous,” he said. “Medical technology will be critical to addressing labour shortages, access challenges and the unsustainable cost pressures facing healthcare systems.”

For Madden, the stakes extend far beyond financial returns.

“The stakes are high,” he added.

“The cost of failure isn’t just financial—it affects patients, health systems and the long-term sustainability of our economies.”

As technology and medicine continue to converge, he believes the medical technology sector will remain one of the most important drivers of change in global healthcare.

“如果你能协调这些利益相关方的激 励措施，就会被接受，”Madden说。

黑暗中闪亮的钻石

该投资理念的例子是OptiMesh，这 是一款由SV Health投资组合中的 公司Spineology开发的脊柱融合 技术。

脊柱融合是美国最常见的外科手术 之一，用于稳定椎骨并减轻因脊柱 不稳定或退行性疾病引起的疼痛。

当SV Health在2024年首次接触到 OptiMesh技术时，Madden形容它 是一款尚未完全实现商业化的创 新产品。

尽管该技术具有显著改善患者疗效 并有为医生和医疗机构带来益处的 潜力，但它却存在于一家历史上一 直难以扩大规模的公司内。

“当我们2024年首次接触到这项技术 时，它极具前景，但却存在于一家尚 未释放其潜力的公司内，”Madden 说。

情况在Spineology任命新首席执行 官Brian Snider后发生了变化，他为 公司带来了新的关注点和运营纪律。

现在，该公司已连续四个季度收入 增长超过20%，同时推出了旨在促 进骨生长和恢复自然脊柱的新植入 技术。

应对医疗行业的最大挑战 展望未来，Madden认为医疗科技 将在解决医疗行业一些最紧迫的结 构性挑战方面发挥核心作用，特别 是在应对成本上升和劳动力短缺的 问题上。

“医疗科技可以通过三种关键方式提 供帮助，”他说，“首先，设备往往旨 在实现确定性干预，而非终身治疗。 其次，微创工具缩短了手术和恢复 时间。第三，人工智能革命将大量采

用医疗设备和传感器生成的高质量 临床数据。”

诸如微创手术工具、临床级可穿戴 设备和人工智能赋能的医疗平台等 技术已经在全球医疗体系中获得 关注。

“老实说，这都让我兴奋，”Madden 说，“每一项创新都代表着每年增长 20-30%的数十亿美元的机遇。”

虚拟医疗和远程患者监测 虚拟医疗平台和远程患者监测技术 也将在医疗服务中发挥越来越重要 的作用。

“虚拟医疗从根本上讲是关于普惠性 的，”Madden说，“在美国，许多人 由于地理位置、交通限制或工作原 因而难以获得持续的医疗服务。远 程医疗可以显著扩展覆盖范围。”

远程患者监测工具提供了额外的便 利：允许临床医生在传统临床环境 之外跟踪患者健康状况。

最终，Madden认为风险投资者和 成长型投资者未来都将在塑造医疗 创新方面发挥关键作用。

通过提供资本、战略指导和运营支 持，投资者可以帮助将有前景的技 术从开发阶段推向广泛的市场应用。

“机遇是巨大的，”他说，“医疗科技 对于解决劳动力短缺、普惠性以及 医疗系统面临的成本压力至关重 要。”

对于Madden来说，赌注远不止于 财务回报。

“赌注很高，”他补充道，“失败的代 价不仅仅是财务上的——它还影响 患者、医疗系统和我们经济的长期 可持续性。”

随着技术和医学的持续融合，他认 为医疗科技行业将继续成为全球医 疗变革的最重要驱动力之一。

Closing the gap:

How Vivasure Medical reinvented vascular closure

More than a decade ago in Galway, Ireland, an entrepreneur and doctor spotted a problem hiding in plain sight inside one of medicine’s fastest-growing fields. Duncan Barry interviews Vivasure Medical’s CEO ANDREW GLASS on what sparked the creation of Vivasure.

Cardiovascular procedures became increasingly minimally invasive, physicians were replacing open surgery with catheterbased treatments performed through the femoral artery in the leg. Procedures such as transcatheter aortic valve replacement (TAVR) and aneurysm repair were transforming patient care.

But they left behind a stubborn challenge.

The devices used in these procedures require large access holes in major blood vessels - holes that are far larger than those used in traditional catheter procedures. Closing them safely and reliably had become one of the most common complications physicians faced.

That challenge sparked the creation of Vivasure Medical.

A startup born in Ireland’s Medtech ecosystem

Vivasure Medical was co-founded in Galway by Mr Ger Brett and Dr Chris Martin, both seasoned entrepreneurs with experience building startups in the medical technology sector. They saw the opportunity to create a simpler, more effective solution for large-hole vascular closure, one that could improve outcomes for both patients and physicians.

Over the past two decades, Ireland has emerged as one of the world’s leading hubs for medical device innovation and manufacturing.

And Ireland proved to be the ideal launchpad.

Mr Glass said: “Over the past two decades, the country has emerged as one of the world’s leading hubs for medical device innovation and manufacturing. Many of the largest global medtech companies operate major facilities there, creating a deep talent pool in engineering, R&D, and advanced manufacturing.

“Vivasure tapped into that ecosystem to build a team capable of taking an ambitious idea from concept to clinic.”

Reinventing how arteries heal

Traditional closure technologies typically rely on either suturebased systems or collagen plugs to seal vascular access sites. While widely used, both approaches have limitations and have been associated with complication rates in complex procedures.

Vivasure took a different path.

Its flagship technology, PerQseal®, uses a fully bioabsorbable patch placed inside the vessel. The patch covers the access hole created during the procedure and is anchored to the vessel wall.

Over time, the body heals over the patch and the material is gradually absorbed, leaving nothing behind. The concept is elegantly simple: restore the artery to its original healthy state, rather than leaving permanent implants.

弥合差距：Vivasure Medical 如何革新血管闭合技术

十多年前，在爱尔兰的戈尔韦，一位企业家兼医生在医学 发展最快的领域发现了一个显而易见却亟待解决的问 题。邓肯·巴里（DUNCAN BARRY）就Vivasure的创立背 景采访了Vivasure Medical的首席执行官安德鲁·格拉斯 （ANDREW GLASS）。

随着心血管手术日益趋向微创化，医生们开始用经股动脉的导管治疗替 代开胸手术。诸如经导管主动脉瓣置换术（TAVR）和动脉瘤修复等手术， 这些正在彻底改变患者的护理方式。

但它们也带来了一个棘手的挑战。

这些手术所用器械需要在主要血管上开较大的孔——这些孔远大于传 统导管手术所用的孔。如何安全可靠地闭合这些孔，减少最常见并发症， 成了医生们面临的问题。

这一挑战催生了Vivasure Medical。

一家诞生于爱尔兰医疗科技生态系统的初创企业 Vivasure Medical由经验丰富的医疗科技领域创业者杰拉德·布雷特 （Ger Brett）和克里斯·马丁（Chris Martin）博士在戈尔韦共同创立。他

们看到了为大型血管闭合创造更简单、更有效解决方案的机遇，这一方 案有望使患者和医生都获益匪浅。

而爱尔兰成为了理想的发源地。

格拉斯表示：“过去二十年来，爱尔兰已成为全球领先的医疗设备创新 和制造中心之一。许多全球最大的医疗科技公司都在此设有重要场所， 培养了工程、研发和先进制造人才库。”

“Vivasure利用这一生态系统，组建了一支能够将雄心勃勃的构想从概念 转化为临床应用的团队。”

动脉愈合方式的革新

传统的闭合技术通常依赖缝合或胶原蛋白塞来封闭血管穿刺点。虽然 这些方法被广泛使用，但都有局限性，并且在复杂手术中并发症发生率 较高。

Vivasure选择了不同的路径。

其旗舰技术PerQseal®采用了一种完全可生物吸收的贴片，置于血管内 部。该贴片可覆盖手术过程中形成的孔，并固定在血管壁上。

The device also offers another practical advantage for physicians. Unlike some competing systems, it requires no preparation before the procedure begins, allowing clinicians to simply deploy the device when the intervention is complete.

In medical technology, particularly with Class III medical devices, the highestrisk category, innovation must operate within a strict framework of regulatory and quality requirements.

“From the beginning, Vivasure placed patient safety and regulatory rigour at the core of its mission.

“Clinical evidence has been central to the company’s strategy. Beyond demonstrating safety and efficacy, the company also focused on improving the real-world clinical experience, including ease of use, speed, and efficiency in hospital settings,” Mr Glass explained.

In medtech, strong clinical trial results alone rarely guarantee success.

Adoption often depends on how seamlessly a device fits into the workflow of busy operating rooms and catheter labs: “Vivasure built its development philosophy around rapid feedback loops with physicians, continuously refining the device based on real clinical use,” he said.

As Vivasure advanced toward commercialisation, the company faced one of the most

challenging phases in the life cycle of any medical device startup: funding and executing a US pivotal clinical trial.

A proud moment

The company raised more than €50 million in a Series D financing round, led by Haemonetics. The funding enabled Vivasure to launch its US IDE pivotal trial while simultaneously continuing development of next-generation products.

The timing, however, was far from ideal.

“The effort unfolded during the COVID-19 pandemic, when fundraising conditions were volatile and global supply chains were under strain.

“Despite those challenges, a relatively small global team coordinated the clinical study while continuing product development, an effort leadership describes as one of the company’s proudest achievements,” Mr Glass said.

As part of the investment, the company received an exclusive option to acquire Vivasure upon reaching certain milestones. After several years of collaboration, Haemonetics exercised that option in late 2025.

The acquisition closed in January in a €185 million transaction, marking a significant milestone for the Galway-based startup.

In an industry where innovation can take years to reach the

bedside, Vivasure’s journey illustrates how a focused clinical insight, paired with disciplined engineering and regulatory execution, can translate into technology that changes the standard of care.

And sometimes, solving one of medicine’s biggest challenges starts with something surprisingly small.

A hole that needs closing.

From the beginning, Vivasure placed patient safety and regulatory rigour at the core of its mission.

随着时间的推移，身体渐渐愈合，贴 片逐渐被吸收，不留任何残留物。这 一过程简单而优雅：恢复动脉至原 始健康状态，而非留下永久植入物。

该设备还为医生提供了另一个优势。

与对抗系统不同，它无需在手术开 始前进行准备，医生只需在干预完 成后部署设备即可。

在医疗科技领域，尤其是对于III类 医疗设备（最高风险类别），创新 必须在严格的监管和质量要求框架 内进行。

“从一开始，Vivasure就将患者安全 和监管严谨性置于核心使命。”

“临床证据一直是公司战略的核心。

除了证明安全性和有效性外，公司 还专注于改善实际临床体验，包括 医院环境中的易用性、速度和效率，” 格拉斯解释道。

在医疗科技领域，仅凭强有力的临 床试验结果很少能保证成功。

设备的采用往往取决于其能否无缝 融入繁忙的手术室和导管实验室的

工作流程：“Vivasure围绕与医生 的快速反馈循环构建了其开发理念， 根据实际临床使用情况不断改进设 备，”他说。

随着Vivasure迈向商业化，公司面 临了医疗设备初创企业生命周期中 最具挑战性的阶段之一：筹集资金 并执行美国关键临床试验。

“这一努力在新冠疫情期间展开，当 时融资条件波动不定，全球供应链 承受压力。

“面临这些挑战，一个小小的国际团 队协调了临床研究，同时继续开发 产品，这一努力被领导层视为公司 最自豪的成就之一，”格拉斯说。

作为投资的一部分，公司获得了在 达到特定里程碑后收购Vivasure 的独家权益。经过数年的合 作，Haemonetics于2025年末行使 了该权益。

从一开始，Vivasure就 将患者安全和监管严谨 性置于核心使命。

自豪时刻

公司在D轮融资中筹集了超过5000 万欧元，由Haemonetics领投。这 笔资金使Vivasure能够启动美国 IDE的关键试验，同时继续开发下一 代产品。

然而，时机并不理想。

收购于1月完成，交易金额为1.85亿 欧元，标志着这家戈尔韦初创企业 取得了重大里程碑。

在一个创新可能需要数年才能应用 于临床的行业，Vivasure的历程展 示了如何将专注临床洞察与严谨的 工程和监管执行相结合，转化为改 变护理标准的技术。

有时，解决医学最大挑战始于一个 看似微不足道的事物。

一个需要闭合的孔。

Wound up for change: Adtec Healthcare’s plasma-powered revolution in infection care

In the evolving landscape of medical technology, few innovations carry the promise of transforming infection management as profoundly as cold plasma therapy. At the forefront of this is MARY MCGOVERN, CEO of Adtec Healthcare, whose journey from plasma technology engineering to medtech leadership reflects both persistence and vision. As antimicrobial resistance continues to rise globally, innovations like Adtec’s Premium Cold Plasma may become an essential part of the healthcare toolkit.

Words by Duncan Barry

“My career began at Adtec Plasma Technology in Japan, where I immersed myself in the technical foundations of plasma-based systems. Working across product design, manufacturing and business development, I helped deliver plasma solutions for the semiconductor and solar manufacturing industries.

“During those early years, I negotiated and managed the company’s first overseas multi-million-dollar customer projects in the United States and Europe,” she recounted, an experience that would later shape her entrepreneurial ambitions.

In the early 2000s, McGovern founded Adtec Europe Ltd to launch the company’s semiconductor and solar businesses across the European market. But as the technology evolved, a new possibility began to emerge. Plasma, long used in industrial manufacturing, showed potential far beyond factories and cleanrooms. McGovern and her team began investing in research and development to explore how plasma technology could be applied to healthcare.

为了变革蓄势 待发：Adtec Healthcare在

感染护理领域 的等离子体技 术革命

在不断发展的医疗技术 领域中，很少有创新能像 冷等离子体疗法那样，对 感染管理带来如此深远 的变革潜力。作为MARY MCGOVERN，Adtec Healthcare的首席执行官， 她的职业生涯涵盖从等离 子体技术工程到医疗科技的 领导，处处展现着其坚持与 远见。随着全球抗菌药物耐 药性的持续上升，像Adtec 的Premium Cold Plasma （优质冷等离子体）这样的创 新，可能会成为医疗工具中 不可或缺的一部分。

Duncan Barry：

“我的职业生涯始于日本的Adtec Plasma Technology公司，在那里 我深入钻研了等离子体系统的技术 基础。我参与了产品设计、制造和业 务开发，帮助为半导体和太阳能制 造行业提供等离子体解决方案。

“在那些早期岁月里，我通过谈判管 理了公司首个在美国和欧洲的数百 万美元海外客户项目，”她回忆道， 这段经历后来塑造了她的创业抱负。

By physically destroying bacteria rather than relying on antibiotics, the technology avoids the cycle of resistance that often undermines conventional treatments.

Those early years required patience. Scientific validation, laboratory testing and clinical trials were essential to demonstrate both safety and therapeutic value. As the evidence base grew, the opportunity became clear: plasma could address one of healthcare’s most persistent challenges: infection.

The result was the creation of Adtec Healthcare, a spinout dedicated to advancing medical applications of plasma technology. At the centre of its innovation is the SteriPlas Premium Cold Plasma device, which is now used across the UK, Europe, the Middle East and Southeast Asia. The technology offers clinicians a new tool in the fight against infection, particularly in chronic and complex wounds.

Unlike traditional antimicrobial treatments that rely on antibiotics or chemical agents, Premium Cold Plasma works through a physical mechanism. The SteriPlas system generates a dense field of reactive plasma that destroys bacteria directly, including multi-drug-resistant

strains and biofilm structures that are notoriously difficult to treat.

For clinicians confronting the global challenge of antimicrobial resistance, this approach represents a significant shift. “By physically destroying bacteria rather than relying on antibiotics, the technology avoids the cycle of resistance that often undermines conventional treatments,” McGovern explains.

The real-world results have been striking. Thousands of clinical treatments have now been carried out using the SteriPlas system, supported by a growing body of peer-reviewed research. What has impressed McGovern most is the speed at which some chronic wounds respond, particularly in cases where conventional therapies have failed.

Complex wounds that once resisted treatment are showing improvement, as plasma disrupts bacterial colonies and biofilms that prevent healing. Because the mechanism is physical rather than pharmaceutical,

21世纪初，McGovern创立了Adtec Europe Ltd，旨在将公司的半导体和 太阳能业务拓展至欧洲市场。但随 着技术的演进，一种新的方式开始浮 现。长久以来一直用于工业制造的等 离子体，其潜力远不止于工厂和洁净 室。McGovern和她的团队开始投资于 研发，探索等离子体技术如何应用于 医疗保健领域。

早期需要极大的耐心。科学验证、实验 室测试和临床试验对于证明其安全性 和治疗价值至关重要。随着证据基础 的积累，机遇变得清晰起来：等离子体 可以解决医疗保健领域一个长期存在 的挑战——感染。

于是，Adtec Healthcare应运而生，这 是一家专注于推进等离子体技术在 医疗领域应用的分拆公司。其创新 的核心是SteriPlas Premium Cold Plasma（优质冷等离子体消毒仪）设 备，该设备现已在英国、欧洲、中东和 东南亚广泛使用。这项技术为临床医 生提供了一种对抗感染的新工具，特别 是在处理慢性复杂伤口方面。

与传统依赖抗生素或化学药剂 的抗菌治疗方法不同，Premium Cold Plasma通过物理机制发挥作 用。SteriPlas系统产生一个密集的活 性等离子体场，直接破坏细菌，包括多 重耐药菌株和顽固生物膜。

对于面临全球抗菌药物耐药性挑战 的临床医生来说，这种方法代表了一 个重大转变。“通过物理方式破坏细 菌，而非依赖抗生素，这项技术避

免了常规治疗中常常反复出现的耐药 性，”McGovern解释道。

实际效果令人瞩目。已有数千例临床治 疗使用SteriPlas系统完成，并得到了 越来越多的同行评审研究的支持。最 让McGovern印象深刻的是，一些对传 统疗法无反应的慢性伤口，在使用该 系统后迅速好转。

随着等离子体对阻碍愈合的细菌群落 和生物膜的破坏，那些曾经难以治疗 的复杂伤口开始改善。由于该机制是

the therapy also prevents both primary and secondary resistance from developing.

With clinical adoption increasing, Adtec Healthcare recently secured a $12 million investment to support its global expansion. The company’s immediate focus is strengthening its presence across Europe, the Middle East, Asia and Australia, while also preparing for one of the most significant milestones in its roadmap: entry into the United States market as Adtec awaits FDA clearance.

Achieving European Medical Device Regulation (MDR) certification for SteriPlas was a major step forward. The rigorous regulatory approval reinforces the device’s safety, quality and clinical value, while opening doors to broader adoption across European healthcare systems.

Beyond wound care, the company is also investigating new applications for its plasma technology. One promising area is postoperative implant treatment, where infection remains a serious risk. Early research is exploring how SteriPlas could reduce infection rates and improve recovery outcomes in patients with implanted devices. The technology is already being studied in the context of large-scale infection management associated with LVAD implants and catheterrelated infections, supported

by clinical evidence from multiple countries.

The company’s roots trace back more than four decades to plasma engineering in Japan, expertise that has been refined and translated into medical innovation.

“Our microwave-generated Cold Plasma has been engineered to deliver treatment safely, reliably and consistently,” McGovern says. “Across two decades of clinical use, there have been no reported side effects.”

Modern clinical research has enabled the development of a particularly dense and stable plasma field, one capable of penetrating deeper into chronic infections rather than just treating surface bacteria.

For McGovern, the mission remains clear: bring a powerful new infection-control technology into everyday clinical practice and improve outcomes for patients worldwide, most especially as bacteria grow more resistant.

物理性的而非药物性的，因此该疗法 还能防止主要和次要耐药性的产生。

随着临床应用的增加，Adtec Healthcare最近获得了1200万美元的 投资，以支持其国际扩张。公司当前的 重点是加强在欧洲、中东、亚洲和澳大 利亚的业务，同时准备迎接其发展路 线图上的一个重要里程碑：进入美国 市场，目前Adtec正在等待FDA的批准。

获得欧洲医疗器械法规（MDR）认证 是向前迈出的一大步。这一严格的监管 批准强化了设备的安全性、质量和临 床价值，同时为其在欧洲医疗保健系 统中的更广泛应用打开了大门。

除了伤口护理外，公司还在探索其等离 子体技术的新应用。一个有前景的领 域是术后植入物的处理，该领域的感 染问题仍是严重风险。早期研究正在 探索SteriPlas如何降低植入物的感染 率并改善康复结果。

该技术已经在与左心室辅助装置 （LVAD）植入物和导管相关感染的大规 模感染管理研究中得到应用，并得到了 来自多个国家的临床证据支持。

公司的根源可追溯到四十多年前日本 的等离子体工程领域，这一专业知识 已被提炼并转化为医疗创新。

“我们的微波产生的冷等离子体经过精 心设计，能够安全、可靠且一致地提供 治疗，”McGovern说，“在二十年的临 床使用中，没有报告过任何副作用。”

现代临床研究使得开发出一种特别密 集且稳定的等离子体场成为可能，这 种等离子体场能够深入穿透慢性感染， 而不仅仅是处理表面细菌。

Our microwavegenerated Cold Plasma has been engineered to deliver treatment safely, reliably and consistently.

对于McGovern来说，使命依然明确： 将一种强大的新型感染控制技术引入 日常临床实践，并改善全球患者的治疗 效果，尤其是在细菌耐药性日益增强 的情况下。

Next generation surgery:

How Medtronic is advancing robotics worldwide

RAJIT KAMAL, Vice President and General Manager of Robotic Surgical Technologies at Medtronic, is helping drive the global roll-out of next-generation robotic-assisted surgery. In this interview with Medtech World’s Duncan Barry, he discusses the mission behind his work, the capabilities of the Hugo™ robotic-assisted surgery (RAS) system, and how innovation in surgical robotics has the potential to improve efficiency, flexibility, and patient outcomes across healthcare systems worldwide.

Rajit Kamal’s journey into medical technology is rooted in both purpose and personal experience. Driven by a desire to make a meaningful impact on patients’ lives, he has built a career focused on advancing healthcare through innovation. Today, as a senior leader at Medtronic, he combines that mission with global reach, an ambition shaped early on by growing up alongside his mother’s gynecological practice in India.

So what is the Hugo™ robotic-assisted surgery system all about?

Rajit said that Hugo is an exciting healthcare technology innovation from Medtronic, furthering the firm’s pursuit to advance patient-care worldwide in partnership with clinicians for 75 years and counting.

Surgical teams across the world use the Hugo™ robotic-assisted surgery (RAS) system to perform over 50 different minimally invasive surgical procedures including prostatectomies, hysterectomies, and hernia repairs.

Hugo’s adoption globally is supported by a growing body of evidence, which has highlighted the system’s differentiated and versatile design:

• Modular robotic components provide flexibility to meet each patient’s unique needs and enable utilization across multiple care settings

• Open console enables high definition 3-D visualization, enhances surgeon ergonomics and OR team communication, and supports training and education for the next generation of surgeons

• Seamless integration with Touch Surgery™ ecosystem puts AI-powered procedural data and analytics at surgeon’s fingertips and enables secure, real-time collaboration among the global surgeon community

• Compatibility with a versatile wristed instrument portfolio built on expertise and technology surgeons have trusted in surgery for decades.

The Hugo™ RAS system is FDA-cleared for urologic surgical procedures in the U.S. Medtronic plans to expand indications in the U.S. to gynecologic and general surgery procedures, including hernia repair. Outside the United States, the Hugo™ RAS system is in clinical use in urologic, general, and gynecologic procedures across major markets.

下一代手术：美 敦力如何在全球 推进机器人手术

RAJIT KAMAL

，美敦力机 器人手术技术副总裁兼总 经理，正助力推动下一代机 器人辅助手术（RAS）系统在 全球推广。在接受Medtech World的Duncan Barry采访 时，他讨论了其工作背后的使 命、Hugo™机器人辅助手术 系统的能力，以及手术机器人 领域的创新如何改善全球医 疗系统的效率、灵活性和患 者预后。

投身医疗科技：初心与个人经历 RajitKamal进入医疗科技领域的旅程， 既源于想要对患者生活产生有意义影 响的愿望，也受到个人经历的启发。他 致力于通过创新推动医疗进步，如今 作为美敦力的高级领导者，他将这一 使命与全球影响力相结合。这一志向 在他成长过程中，受其母亲在印度从 事妇产科实践的影响而很早就形成。 Hugo™机器人辅助手术系统简介

Rajit介绍说，Hugo™是美敦力一项激 动人心的医疗技术创新，进一步推进了 公司75年来与临床医生合作改善全球 患者护理的追求。

全球的手术团队使用Hugo™机器人辅 助手术系统进行了超过50种不同的微 创手术，包括前列腺切除术、子宫切除 术和疝修补术。

Hugo™在全球的应用得到越来越多证 据的支持，这些证据突出了该系统差 异化且多功能的设计：

What’s in for patients

“Efficient surgery is good for patients and hospitals. Medtronic surgical technologies, and our commitment to training, service, and support for OR teams, have contributed to enhanced procedural efficiency across modalities for decades,” Rajit explained.

“The Hugo™ RAS system and our partnership to build and grow robotic programs extend the value we offer to customers. This is more important than ever as U.S. hospitals seek to manage capacity challenges, economic and staffing pressures, and an aging population and higher burden of disease,” he told Medtech World.

Within the OR, Hugo's modular design provides surgeons flexibility to adapt their approach to meet the needs of each procedure and patient. The portable robotic arms also move easily to optimize scheduling and help reduce downtime between cases.

The importance of flexibility

Medtronic thinks about flexibility in a few ways. It starts with providing surgeons and hospitals choice in technology and partnership across all modalities of surgery, open, laparoscopic, and roboticassisted. Today, Medtronic is the only company able to deliver that value to customers.

“Within surgery, each patient is unique. Hugo's modular architecture and multiquadrant access give surgeons the ability to optimize the procedure based on what the case demands. That flexibility also means one system can handle a variety of procedures and mobility means it can be used in different ORs,” Rajit highlighted.

Robotic-assisted surgery adoption is growing, but there’s still a massive opportunity to reach more patients.

Today, more than half of the 60 million soft-tissue surgeries performed globally each year are done as open procedures. That’s more than 30 million patients who don’t have access to the benefits of minimally invasive surgery such as fewer complications, shorter hospital stays, and faster recoveries. Robotic and digital technologies like the Hugo™ RAS system and Touch Surgery™ ecosystem are helping to bring the benefits of minimally invasive surgery to more patients in more places. Today, the Hugo™ RAS system is in clinical use in more than 35 countries across five continents.

Rajit said scaling robotics requires significant investment, noting that Medtronic is doing so from a place of strength given its global leadership in surgery.

“You’re not just selling a robot. With Medtronic, we are offering a partnership backed by a commitment to training,

support, and service to help our customers achieve their goals. Together, our differentiated technology and approach to partnership, including the flexibility of multiple acquisition models, are designed to overcome barriers to broader adoption, so more patients have access to roboticassisted surgery,” he said.

Within surgery, each patient is unique.

Hugo's modular architecture and multiquadrant access give surgeons the ability to optimize the procedure based on what the case demands.

· 模块化机器人组件：提供灵活性 以满足每位患者的独特需求，并可 在多种护理环境中使用。

· 开放式控制台：提供高清3D可视 化界面，改善外科医生人体工学 和手术室团队的沟通，并支持下一 代外科医生的培训和指导。

· 与Touch Surgery™生态系统的 无缝集成：将人工智能驱动的手 术数据和分析置于外科医生指尖， 并促进全球外科医生社区之间的 实时安全协作。

· 兼容多功能腕式器械组合：基于 外科手术医生数十年来信赖的专 业知识和技术构建。

Hugo™ RAS系统已获得美国食品 药品监督管理局（FDA）批准，用于 美国的泌尿外科手术。美敦力计划 将该系统在美国扩展至妇科和普 通外科手术，包括疝修补术。在美 国以外，Hugo™ RAS系统已在主要 市场用于泌尿外科、普通外科和妇 科手术。

对患者的益处

“高效的手术对患者和医院都有好处。 几十年来，美敦力的手术技术以及对 手术室团队的培训、服务和支持，提 高了各种手术方式的效率，”Rajit 解释道。

“Hugo™ RAS系统以及我们合作建 立和发展机器人手术项目的努力，延 伸了我们为客户提供的价值。在美 国医院努力应对承载、经济和人员 压力以及人口老龄化和疾病负担 加重的背景下，这一点比以往任何 时候都更重要，”他告诉Medtech World。

在手术室内，Hugo™的模块化设计 使外科医生能够灵活调整手术方法， 以满足手术和患者的需求。便携式 机械臂也易于移动，以优化手术安 排并减少手术之间的停机时间。

灵活性的重要性

美敦力从几个方面考虑灵活性。首 先是为外科医生和医院在所有手 术方式（开放、腹腔镜和机器人辅 助）中提供技术和合作。今天，美敦 力是唯一能够为客户提供这种价值 的公司。

“在手术中，每位患者都是独特 的。Hugo™的模块化架构和多象限 访问使外科医生能够根据手术需求 优化手术。这种灵活性还意味着一 个系统可以处理多种手术，并且其移 动性意味着它可以在不同的手术室 中使用，”Rajit强调道。

机器人辅助手术的未来

机器人辅助手术的应用正在增长， 且仍有机会接触到更多患者。

今天，全球每年进行的6000万例软 组织手术中，超过一半是开放手术。 这意味着有超过3000万患者无法 享受到微创手术的好处，如并发症

减少、住院时间缩短和更快的恢复 时间。像Hugo™ RAS系统和Touch Surgery™生态系统这样的机器人 和数字技术正在将这些微创手术的 好处带给更多的患者。今天，Hugo™ RAS系统已在五大洲的35多个国家 投入临床使用。

Rajit表示，扩大机器人手术的规模 需要大量投资，并指出美敦力凭借 其在手术领域的全球领导地位，正 进行强势投资。

“你不仅仅是在销售机器人。在美敦 力，我们提供的是一种合作关系，并 承诺提供培训、支持和服务，以帮助 我们的客户实现目标。我们差异化 的技术和合作方式以及多种采购模 式的灵活性，旨在克服广泛应用的 障碍，使更多患者能够用上机器人 辅助手术，”他说。

The American Heart Association:

A catalyst for innovation

In this Medtech World Q&A interview, the AMERICAN HEART ASSOCIATION’S CENTER FOR HEALTH TECHNOLOGY & INNOVATION outlines its mission to bridge science and technology, sharing insights into how AI, digital health, and collaborative ecosystems are driving a shift towards more proactive and patient-centred care.

The Center for Health and Technology and Innovation operates at the intersection of science and technology. How would you describe its core mission in today’s evolving healthcare landscape?

For 100 hundred years, the American Heart Association has been a catalyst for innovation, driven by our founder’s belief in the transformative power of science and research.

Now, in our second century, the Association is driving a new era of health innovation, where trusted science, patient-centered technology and measurable clinical outcomes come together to transform care and improve lives for all.

The Center for Health Technology & Innovation convenes digital health, health tech and AI solutions with trusted science ensuring innovation is evidenced-based and built to truly improve care.

As healthcare shifts upstream, CHTI helps distinguish what’s promising from what’s proven, accelerating solutions that deliver earlier, more effective patient care.

It's not innovation for innovation’s sake, it’s grounded in the American Heart Association’s science and focused on what actually improves care.

What key healthcare challenges, particularly in cardiovascular and brain health, are you aiming to solve through innovation?

Shifting cardiovascular and brain health from reactive, episodic care to proactive, continuous care that reaches people earlier. Too many conditions are still detected after a major event, despite what we know from decades of science. By convening digital health, health tech, and AI with trusted evidence, we’re working to turn fragmented data into meaningful, actionable insights and extend guidelinebased care beyond the clinic into homes and communities. The goal is to enable earlier detection, smarter intervention and direct access so we improve outcomes before conditions escalate, not just after.

What differentiates your approach from other health innovation hubs?

What sets the Center for Health Technology & Innovation apart is that it’s not innovation for innovation’s sake, it’s grounded in the American Heart Association’s science and focused on what actually improves care. That means bringing digital health, health tech, and AI together with trusted evidence, and working alongside health systems, clinicians, and innovators to make sure solutions are not only promising, but proven and usable in the real world. It’s less about showcasing what’s new, and more about advancing what works, so we can scale solutions that meaningfully improve cardiovascular and brain health outcomes.

What does an ideal innovation ecosystem look like in practice?

At CHTI, collaboration isn’t a principle, it’s how the work gets done. It starts with our volunteer experts like clinicians, researchers, scientists and innovators, who bring realworld insight into delivering care. From there, we tap into the broader engine of the American Heart Association, its science, guidelines and community reach, depending on the goal.

And in some cases, it extends into deeper, purpose-built collaborations like AHA Connected Care™ powered by Cadence, a virtual, at-home care model for conditions like heart failure and hypertension that combines AHA’s evidencebased care plans with remote monitoring, continuous clinical oversight and integration with health systems, but delivered at home where patients need care the most.

What role do technologies like AI, digital therapeutics, and remote monitoring play in shaping your current priorities?

At CHTI, technologies like AI, digital therapeutics and remote monitoring come to life through the Innovators’ Network, a community of innovative solutions working to transform cardiovascular and brain health. Our focus is on helping them align with trusted science and integrate into real-world care.

The Innovators’ Network brings together startups, health systems, researchers, and industry players, what makes this ecosystem unique?

What makes the Innovators’ Network unique is that it’s not just a network, it’s anchored in the American Heart Association’s science and built for real-world impact. It brings innovators, health systems, researchers, and industry together around a shared standard of evidence, giving innovators direct access to clinical expertise, validation pathways and care delivery environments.

What types of organisations or innovators benefit most from joining the Network?

The Innovators’ Network is best suited for organizations building solutions in cardiovascular and brain health, especially those leveraging AI, digital health, or data-driven care. They are

beyond the start up phase and commercially in the market. Even established players benefit when they’re looking to validate their solutions with trusted science, connect with clinicians and health systems, and accelerate adoption in care delivery.

What role do events play in connecting innovators with investors, clinicians, and partners?

Events, showcases and Scientific Sessions are where connection turns into momentum. These platforms create a trusted environment for innovators to engage directly with clinicians, scientists and partners, a place to showcase solutions, gain real-time feedback and build relationships needed to validate, refine and scale. It’s about accelerating adoption and bringing the right people together.

What opportunities exist for global collaboration, especially with organisations outside the US?

There’s strong opportunity for global collaboration through shared science, scalable digital solutions and global alliances with health systems, innovators, and researchers. CHTI helps connect organizations beyond the U.S. into a broader ecosystem.

美国心脏协 会：创新的 催化剂

在本次Medtech World的采访中，美国 心脏协会的健康技术 与创新中心阐述了其 连接科学与技术的使命， 分享了人工智能、数字 健康及合作生态系统 如何推动医疗向更积 极地以患者为中心的 方向转变的见解。

健康技术与创新中心处于 科学与技术的交汇点。在 当今不断演变的医疗环 境中，您如何描述其核心 使命？ 百年来，美国心脏协会一直 是创新的催化剂，这源于我 们创始人坚信科学研究的变 革力量。

如今，在第二个百年里，协会 正推动健康创新的新纪元，

The goal is to enable earlier detection, smarter intervention and direct access so we improve outcomes before conditions escalate, not just after.

将值得信赖的科学、以患者为中心 的技术和可衡量的临床结果相结 合，以改变医疗护理并改善所有人 的生活。

健康技术与创新中心将数字健康、 健康科技和人工智能解决方案与值 得信赖的科学相结合，确保循证创 新，并真正旨在改善医疗护理。

随着医疗向上游转移，CHTI帮助区 分哪些是有前景的，哪些是经过验 证的，加速提供更早、更有效的患者 护理解决方案。

您通过创新旨在解决哪些关键 的医疗挑战，特别是在心血管 和脑健康方面？

将心血管和脑健康从被动的、偶发 的护理转变为积极的、持续的护理， 进行更早的干预。尽管数十年的科 学告诉我们许多信息，但仍有太多 病症是在出现严重症状后才被检 测出来。通过将数字健康、健康科 技和人工智能与值得信赖的证据相 结合，我们正努力将碎片化的数据 转化为有意义且可操作的医疗知识， 并将可指导的护理扩展到诊所之外， 进入到家庭和社区。目标是实现更 早的检测、更智能更直接的干预，以 便在病情恶化之前改善疗效，而不 仅仅是在病情恶化之后。

您的创新方法与其他健康创新 中心有何不同？

健康技术与创新中心的不同之处在 于，它不是为了创新而创新，而是基 于美国心脏协会的科学，并专注于 真正改善护理的内容。这意味着将 数字健康、健康科技和人工智能与 值得信赖的证据相结合，并与医疗 系统、临床医生和创新人员合作，确 保解决方案不仅是有前景的，而且 是在现实世界中经过验证有效的。

这与其说是展示新事物，不如说是 推进有效的事物，以便我们可以扩 大解决方案，有意义地改善心血管 和脑健康。

理想的创新生态系统在实践中 是什么样的？

在CHTI，合作不是原则，而是工作 的方式。它始于我们的志愿者专家， 如临床医生、研究人员、科学家和 创新人员，他们为提供护理带来实 践经验。然后，我们根据目标，利用 美国心脏协会的广泛力量，包括其 科学、培训和社区影响力。

在某些情况下，它会延伸到更深层 次的特定合作，如AHA Connected Care™（由Cadence提供支持），这 是一种针对心力衰竭和高血压等 疾病的虚拟家庭护理模式，结合了 AHA循证护理计划、远程监控、持 续的临床监督和医疗系统的集成， 在患者最需要的地方——家中提供 护理。

人工智能、数字疗法和远程监 控等技术如何塑造您当前的优 先事项？

在CHTI，人工智能、数字疗法和远 程监控等技术通过创新网络得以实 现，这是一个致力于改变心血管和 脑健康的创新解决方案社区。我们 的重点是帮助他们与值得信赖的 科学保持一致，并融入现实世界的 护理中。

创新者网络汇聚了初创企业、医 疗系统、研究人员和行业参与 者，是什么使这个生态系统独 一无二？

创新网络的独特之处在于，它不仅 仅是一个网络，它根植于美国心脏 协会的科学，并为现实世界的影响 而建立。它围绕共同的标准证据将 创新人员、医疗系统、研究人员和 行业聚集在一起，以便创新人员直 接访问临床专业知识、验证途径和 护理环境。

哪些类型的组织或创新者最能 从加入网络中受益？ 创新网络最适合那些在心血管和脑 健康领域构建解决方案的组织，特 别是那些利用人工智能、数字健康 或数据驱动护理的组织。他们已经 度过了初创阶段，并在市场上实现 了商业化。即使是成熟企业，当他们 希望用值得信赖的科学验证其解决 方案、与临床医生和医疗系统建立 联系，促进其被医疗机构采纳时，也 能从中受益。

活动在连接创新人员与投资方、 临床医生和合作伙伴方面扮演 什么角色？

活动、展示会和科学会议是将连接 转化为动力的地方。这些平台为创 新者提供了一个值得信赖的环境， 让他们可以直接与临床医生、科学 家和合作伙伴互动，展示解决方案、 获得实时反馈并取得联系，以验证、 完善和扩大规模。这是为了互相了 解并将合适的人聚集在一起。

全球合作的机会有哪些，特别是 与美国以外的组织？

通过共享科学、可扩展的数字解决 方案和与医疗系统、创新和研究人 员的全球联盟，存在广泛的全球合 作机会。CHTI可以将美国以外的机 构连接到一个更广泛的生态系统中。

Florida’s Life-Sciences moment:

Turning momentum into market leadership

In this interview with Duncan Barry, the President & CEO of BioFlorida, MARK GLICKMAN, discusses where innovation truly begins, the risks of fragmentation, and how Florida can transition from an emerging player to a global destination for life sciences.

Florida’s life sciences sector is at a pivotal moment, transitioning from an emerging ecosystem into a serious global contender.

For Mark Glickman, success is measured by tangible outcomes, not just activity.

“For me, that means increased capital flowing into Florida companies, more clinical and commercial-stage companies choosing to build and stay here, and stronger connectivity across our ecosystem. If we are consistently attracting top-tier talent, expanding partnerships with global biopharma, and seeing our universities translate innovation into funded companies and real products, then we are doing our job. Ultimately, success is when Florida is not viewed as an emerging market, but as a destination,” Glickman said.

Innovation begins with people and unmet need: Glickman

“It often starts in academia or at the bench, but it only becomes meaningful when it is connected to realworld application. The most impactful innovation happens when science, capital, and experienced operators come together early. I’ve seen great ideas fail because they lacked that connection, and I’ve seen modest ideas succeed because the right ecosystem was built around them,” the CEO and President of BioFlorida explained.

Striking

a balance while keeping a clear strategic direction

As BioFlorida works across research, startups, and policy; it manages to balance these priorities while keeping a clear strategic direction.

“The key is alignment around a single objective: advancing the ecosystem. Research, startups, and policy are not separate lanes, they are interdependent. Strong policy enables growth, research fuels innovation, and startups translate that into economic and patient impact.

“Our role is to act as the connective tissue, ensuring these elements are coordinated and moving in the same direction. We stay focused by prioritizing initiatives that drive measurable outcomes across all three areas.”

And the biggest opportunity for Florida’s life sciences ecosystem right now is momentum.

“Florida is attracting talent, capital, and attention at a level we haven’t seen before. If we continue to build the right infrastructure, particularly around early-stage funding and company formation, we can accelerate quickly,” Glickman said.

And the the biggest risk, according to Glickman, is fragmentation.

“If we don’t stay coordinated as an ecosystem, we risk missing the opportunity

to scale. We need to ensure that our universities, companies, investors, and policymakers are aligned and working toward a shared vision,” he warned.

Connecting early-stage innovation with real

market success

This process, Glickman said, begins with intentional connectivity across the entire life sciences ecosystem.

Early-stage innovation cannot thrive in isolation; it requires timely access to capital, experienced mentorship, and meaningful industry validation much earlier than is often the case. Without these elements, even the most promising scientific breakthroughs risk stalling before they reach commercial viability.

“Programmes such as LaunchPad are specifically designed to address this gap by creating structured opportunities for engagement, bringing together investors, academic institutions, seasoned operators, and emerging companies in a way that fosters collaboration and accelerates development pathways.

Beyond structured programmes, there is also a broader need to cultivate a culture of continuous interaction between key stakeholders. Strengthening these relationships ensures that innovation is not only nurtured but also guided toward real-world application.

The government plays a foundational pillar and can help set priorities, provide funding, and remove barriers, while the private sector brings speed, execution, and market discipline to the table.

“Besides, we need to continue building bridges between academia and industry so that promising technologies don’t stall before commercialisation,” Glickman highlighted, underscoring the importance of sustained collaboration. By aligning scientific discovery with market needs from an early stage, ecosystems can significantly improve the success rate of translating research into impactful, scalable solutions.

And what role should public-private collaboration play in accelerating scientific progress?

Glickman explains that this should be foundational.

“The government plays a foundational pillar and can help set priorities, provide funding, and remove barriers, while the private sector brings speed, execution, and market discipline to the table.

“When the abovementioned two aspects are aligned, progress accelerates significantly.

“We’re seeing that more in Florida now, and it is critical that we continue to strengthen those partnerships to compete on a national and global level,” Glickman concluded.

佛罗里达生命科学：将发展势 头转化为市场领导力

在本次对BioFlorida, MARK GLICKMAN总裁兼首席执

行官邓肯·巴里的采访中探讨了创新的真正起点、碎片 化的风险，以及佛罗里达如何从新兴的参与者转变为全 球生命科学的圣地。

佛罗里达的生命科学领域正处于关键时刻，正从一个新兴生态系统转变 为全球重要的竞争参与者。

对于马克·格利克曼来说，成功是以实际成果来衡量的， 而不仅仅是活动。

“对我而言，这意味着更多的资本流入佛罗里达的公司，更多临床和商业 化阶段的公司选择在这里建立并留下来，以及我们生态系统内部更加 巩固。如果我们能持续吸引顶尖人才，扩大与全球生物制药公司的合作， 并看到我们的大学将创新转化为公司资本和实际产品，那么我们的工作 就有意义。最终，当佛罗里达不再被视为一个新兴市场，而是一个目标 时，我们就成功了，”格利克曼说道。

创新始于人才和未满足的需求：格利克曼 “创新通常始于学术界或实验室，但只有当它与实际应用相结合时，才变 得有意义。最具影响力的创新发生在科学、资本和经验丰富的运营者的 早期结合。我见过一些伟大的思想因为缺乏这种联系而失败，也见过一 些平凡的想法因为建立了正确的生态系统而成功，”BioFlorida的首席 执行官兼总裁解释道。

在保持清晰战略方向的同时取得平衡 BioFlorida在前期调研、初始创业和后期政策中，能够平衡这些优先事 项，同时保持清晰的战略方向。

“关键在于始终围绕一个目标推动生态系统发展。前期调研、初始创业和 后期政策并非独立的领域，而是相互依存的。强有力的政策可促进增长， 调研可推动创新，初始创业则将这种创新转化为经济价值和长远影响。

“我们的角色是作为纽带，确保这些要素协调一 致，朝着同一方向前进。我们通过优先推动在这 三个领域都能产生成果的计划来保持专注。”

对于佛罗里达的生命科学生态系统来

说，目前最大的机遇就是发展势头。

“佛罗里达正在以前所未有的水平吸引人才、资本和关 注。如果我们继续建立正确的基础，特别是在早期融资 和公司创建时，我们就能迅速发展，”格利克曼说道。

而格利克曼认为，最大的风险是碎片化。

“如果我们不能作为一个生态系统保持协调，我 们就可能错失扩大规模的机会。我们需要确 保我们的大学、公司、投资者和政策制定者保 持一致，朝着共同的愿景努力，”他警告道。

将早期创新与实际市场连接起来 格利克曼说，这个过程始于整个生 命科学生态系统的融合。

早期创新不能孤立存在；它需要尽早获得资本、经验丰富 的指导和有意义的行业验证。没有这些要素，即使最有 前途的科学突破也可能在达到商业可行性之前停滞不前。

“像LaunchPad这样的计划就是专门来填补 这一空白的，通过创造结构化的参与机会，将 投资者、学术机构、经验丰富的运营方和新兴 公司聚集在一起，促进合作并加速发展。

除了结构化方案外，还需要在关键利益相关方之间 促进持续互动。加强这些关系可以确保创新不仅可 以获得养分，还能得到指导，并走向实际应用。

“此外，我们需要继续在学术界和产业界之间搭建桥 梁，以确保有前景的技术在商业化之前不会停滞不 前，”格利克曼强调了持续合作的重要性。通过从早期 阶段就将科学研究与市场需求相结合，可以显著促进 将科学研究转化为有影响力力的、可扩展的解决方案。

那么，公私合作在加速科学进步方 面应该扮演什么角色呢？ 格利克曼解释说，应该是基础性的。

“政府扮演着基础支柱的角色，可以帮助设 定优先事项、提供资金并消除障碍，而企 业则带来速度、执行力和市场纪律。

“当上述两个方面保持一致时，进展就会显著加速。

“我们现在在佛罗里达看到了更多这样的情况，继 续加强这些合作伙伴关系对于我们在国家和全球 层面上的竞争至关重要，”格利克曼总结道。

Who’s Who Directory

alirahealth.com

Alira Health is a global healthcare consultancy redefining evidence generation through patient partnership. By uniting strategic consulting, CRO services, and technology, the company supports life sciences organizations in accelerating development, improving access, and delivering measurable outcomes across the product lifecycle.

Ainoa Forteza

Vice President, Regulatory Affairs, Alira Health

bluegoatcyber.com

Blue Goat Cyber supports medical device teams in meeting FDA cybersecurity requirements. Its services include threat modelling, SBOM support, penetration testing and documentation, helping companies streamline submissions, reduce review friction and launch connected products securely and efficiently.

Christian Espinosa

Founder

and CEO, Blue Goat Cyber

ascendcro.com

Ascend CRO is a next-generation clinical research organization that helps medtech innovators move faster from idea to evidence. Blending regulatory expertise, agile trial design, and handson execution, Ascend turns complex clinical studies into clear, efficient pathways–accelerating development while maintaining uncompromising scientific and operational quality.

Jules Bligh

Operations Director, Ascend Clinical

byonyks.com

Byonyks is redefining dialysis through its FDA-cleared APD Cycler X1, enabling bloodless, needle-free home treatment. Focused on accessibility and ease of use, the company aims to expand home dialysis adoption while preparing for US patient treatments and broader market impact.

Farrukh Usman Founder & CEO, Byonyks

beaconlaunchpartners.com

Beacon is a medtech product development partner offering endto-end services, including design, prototyping, research, regulatory submissions and quality systems. Its multidisciplinary team supports innovators in bringing healthcare technologies to market within regulated environments.

Myra Fabro Managing Partner, Beacon Launch Partners, LLC

complywise.cloud

ComplyWise is a clinical integrity intelligence platform that connects and validates data across clinical, financial and compliance workflows. It helps healthcare organisations reduce risk, improve efficiency and ensure data accuracy before entering critical systems.

Murthy Anupindi Founder/CEO, COMPLYWISE LLC

cslifesciences.com

CS Lifesciences is a USA, UK, and Ireland-based consultancy providing end-to-end Quality, Clinical, and Regulatory support for Medical Devices, IVD, and Clinical Diagnostics. We help you build QMS, run clinical studies, manage FDA and CE submissions, and deliver post-market support with practical, hands-on expertise.

Edwin Lindsay Managing Director, CS Lifesciences

neopredics.com

NeoPredics is a digital health company developing predictive analytics software for maternal and neonatal care. Its platform uses medical data to forecast risks such as preeclampsia and neonatal complications, enabling earlier interventions, personalized treatment, and improved clinical decision-making to enhance outcomes for mothers and newborns.

Thorsten Waloschek CEO, NeoPredics

igenticai.com

i-GENTIC is a next-generation agentic governance platform built by industry experts to elevate regulatory and compliance intelligence in MedTech and other highly regulated sectors. Proven in real-world use, it has identified issues overlooked in traditional review processes and delivers scalable, multilingual, auditready oversight powered by globally experienced leadership.

Zahra Timsah Chief Executive Officer, i-GENTIC AI

paltech.fr

Paltech is a Paris-based biotech developing a first-in-class implantable therapy to restore glucose sensing at the portal vein and re-establish natural insulin regulation. With strong preclinical results and patented technology, Paltech aims to deliver a curative solution for type 2 diabetes and metabolic diseases.

Dr Reginald Allouche CEO, PALTECH

medmarc.com

Created in 1979, Medmarc’s mission is to be the superior provider of liability insurance and related risk management solutions. We support the development, testing, and delivery of medical products that save lives and improve the quality of life. Call us to discuss your needs regarding insurance coverage (703) 652-1360.

Lynn Carney Director, Agency and Alliances, Medmarc

podymos.com

Podymos is a specialist MedTech marketing agency founded in 2016, operating across 30+ medical specialties in the UK, EU, and US. Offering messaging, branding, and online and offline campaigns. Podymos accelerates device adoption through content-led strategies. Podymos is StoryBrand, Endless Customers, and HubSpot certified, with 1,000+ projects delivered to date.

Claudia Holy Founder and CEO, Podymos

projectusconsulting.com

Projectus Consulting is a specialist talent consultancy focused on the global medical technology sector. The company partners with MedTech organisations to identify, attract, and place high-calibre professionals across the entire product lifecycle, from R&D and engineering to regulatory, clinical, and commercial roles, supporting innovation and business growth.

Tim Lawrie Founder and CEO, Projectus

prolucid.ca

Prolucid is an ISO-certified software engineering firm with over 18 years of experience in the global field. Prolucid builds custom software applications that support web and cloud application development, AL, ML, computer vision, and custom algorithm integration, data acquisition, processing, storage, custom visualization, and quality, regulatory, and cybersecurity support and compliance.

Chris Kennedy VP, Partnerships, Prolucid

serenarx.com

Serena Health is a healthcare technology company focused on improving access to personalised care through compliant digital infrastructure, patient acquisition systems and pharmacy-integrated telehealth solutions, supporting scalable and modern healthcare delivery.

Sebastian De Bono

CEO,

Serena Health LLC

skuvent.com

Skuvent delivers purpose-built software for medical device field inventory management. Designed from the ground up to meet the operational realities of medtech companies, from expirations to the challenges of maintaining traceability of trunk stock & inventory across the field. The result: operational clarity for reps and complete traceability for ops.

Maunark Patel

Co-Founder,

CEO, Skuvent Inc

qrxpartners.com

QRx Partners helps MedTech companies build practical regulatory strategies and risk-based quality management systems that withstand regulatory body scrutiny. aWe turn compliance from a reactive burden into a strategic advantage, delivering clear roadmaps, disciplined execution, and credibility with regulators and investors alike.

Steve Gompertz & Mark Swanson Partner, QRx Partners

vektormedical.com

Vektor Medical is redefining arrhythmia care with vMap, the only FDA-cleared and CE-marked, non-invasive technology that uses standard 12-lead ECG data to help physicians localize arrhythmia sources across all four chambers of the heart. Clinical data demonstrates that vMap improves outcomes, enhances efficiency, and enables more targeted ablation.

Rob Krummen CEO, Vektor Medical

vitvio.com

VitVio is an AI platform transforming operating rooms with real-time surgical intelligence. Using computer vision and advanced analytics, VitVio helps hospitals improve efficiency, optimize workflows, and enhance patient care by turning operating room activity into actionable insights for surgical teams and healthcare operators.

Dr David L Rawaf

CMO/Clinical Director, VitVio

MedTech World

Speakers

alirahealth.com

Mercè is a regulatory strategy expert specializing in the medtech space, including FDA clearances, CE marking, and breakthrough device designations. Mercè also brings experience in drug development, with a strong background in EMA and FDA procedures. She holds degrees in Human Biology and Pharmaceutical Biotechnology, and has expertise in regulatory strategies across medical devices and digital therapeutics.

Mercè Guerra

Associate Director, Regulatory Affairs Medtech, Alira Health

bluegoatcyber.com

Christian Espinosa, a service-disabled veteran and founder of Blue Goat Cyber, has led medical device cybersecurity since 2014. A heavy metal fan, Formula 4 racer, and 24-time Ironman finisher, he drives teams to FDA-ready proof.

Christian Espinosa

Founder and CEO, Blue Goat Cyber

ascendcro.com

Ascend is Australia’s/Australasia’s premier med tech clinical research partner for FIH, pivotal and post market studies – with premium access to animal labs, site and KOL outreach, development, ethics submissions, governance, and monitoring. Recognised by FDA, CE as a Center of Excellence.

Joseph Panetta

Chief Marketing Officer, Ascend Clinical

byonyks.com

Farrukh Usman is the Founder and CEO of Byonyks, a medical device company focused on dialysis technology. He led the team that secured FDA clearance for the Byonyks X-1 Cycler, advancing renal care with innovative dialysis systems.

Farrukh Usman

Founder & CEO, Byonyks

capitalanalyticsassociates.com

Abby Lindenberg is a founder-led CEO and national business strategist. Lindenberg built Capital Analytics (caa) without outside investors - a media and intelligence platform now spanning 18 U.S. regions. Through Invest: reports, leadership summits, and executive forums, she has convened thousands of CEOs, investors, and public-sector leaders, and moderated conversations with governors, mayors, and top executives shaping regional economies across the country.

Abby Lindenberg Founder and CEO, caa

cozen.com

Chris provides sophisticated transactional and regulatory counsel to an array of health care providers and investors in the health care industry.

R. Christopher Raphaely Co-Chair, Health Care & Life Sciences Practice, Cozen O’Connor

my.clevelandclinic.org/innovations

With over 20 years of experience in healthcare investing, innovation leadership, investment banking, and consulting, Todd Schwarzinger brings deep expertise in identifying, supporting, and scaling healthcare technology companies that advance patient care and drive meaningful innovation.

Todd Schwarzinger Partner, Innovations Ventures, Cleveland Clinic Innovations

cognixion.com

Andreas Forsland is Founder and CEO of Cognixion, pioneering noninvasive brain-computer interfaces integrated with AI and AR to expand communication access for people with neurological conditions. Cognixion has received FDA Breakthrough Device Designation and was named one of TIME’s Best Inventions of 2025.

Andreas Forsland Founder & CEO, Cognixion

Danielle is a healthcare & life sciences transactions attorney advising clients on due diligence, compliance, licensing, regulatory filings and operational transition issues.

Danielle E. Sapega Member, Cozen O’Connor

cslifesciences.com

Edwin is Managing Director and Principal Consultant with 20+ years in life sciences and medical devices/ IVD. He specialises in regulatory affairs, clinical operations and quality, with FDA and CE approval experience. He advises startups and established manufacturers, lectures at Strathclyde and Glasgow, and co-founded Sure Retractors Inc.

Edwin Lindsay

Managing Director/Principal Consultant, CS Lifesciences

cslifesciences.com

Quality, Regulatory, Clinical consultant over 25 years medical device experience. Real passion for working with innovators to get new products to market. Extensive experience in US, EU and Japanese clearance and regulatory strategies.

Angela Paterson

Principal Consultant, CS Lifesciences

deloitte.com

Brad endeavors to bring a practical, evidence-based perspective to NeuroTech, drawing on experience across neuromodulation, medtech strategy, and market access. His presentations focus on helping leaders connect innovation, commercialization, and real-world adoption dynamics in ways that are pragmatic and effective.

Brad Maruca

Managing Director, Deloitte

excelestarventures.com

Tasneem Dohadwala is the Founding Partner of Excelestar Ventures, focusing on promising investments in medical and deep technology. Her prior experience includes positions at Lehman Brothers and Matrix Partners. Under her leadership, Excelestar Ventures was recognized as one of the top 100 Women-Led Businesses in Massachusetts by The Boston Globe.

Tasneem Dohadwala

Founding Partner, Excelestar Ventures

ey.com

Experienced Investment Banking professional with 20+ years of focus on healthcare sector M&A advisory across major Wall Street Banks, including Goldman Sachs, Credit Suisse, and Barclays. Advised corporate management teams and Corporate Boards on both public and private M&A transactions, worth over $120B in cumulative transaction value.

Abhi Akkapeddi Managing Director, EY Capital Advisors

endiatx.com

Arman Nadershahi is CEO of Endiatx, a medical device company developing swimming robotic capsules for diagnostics and therapy inside the human body. He has led the advancement of investigational endoscopic capsules PillBotâ and Flowerâ, from concept to precommercial trials, integrating robotics, imaging, and AI to transform gastrointestinal diagnostics.

Arman Nadershahi CEO, Endiatx

FHA.Org

Mary C. Mayhew serves as the President and CEO of the Florida Hospital Association. Under her leadership and in partnership with Florida’s hospitals, Mayhew has focused the organization’s efforts to transform the delivery of health care to support a modern, sophisticated system that can respond to the evolving needs of Florida’s citizens and visitors alike.

Mary C. Mayhew

President and CEO, Florida Hospital Association

cloud.google.com

Dr. Joe Shonkwiler leads Google Cloud’s healthcare and life science startup practice. He was the founding COO of ARPA-H, managing $3B in biomedical investments. Previously, he held leadership roles at AWS and Aledade, and served as a Health Policy Advisor in the U.S. Senate. He holds degrees from Notre Dame, Columbia, MIT, and Princeton.

Joe Shonkwiler, MD Healthcare and Life Science Lead, Venture Capital BD, Google

hrsonline.org

Christina Wurster, MBA, CAE, is the CEO for the Heart Rhythm Society, a 9,000+ member professional society. Its goal is to end death and suffering due to heart rhythm disorders. Wurster is focused on fulfilling the Society’s mission to improve the care of patients by promoting research, education, and optimal health care policies and standards.

Christina J. Wurster

Chief Executive Officer, Heart Rhythm Society

gunster.com

Senator George S. LeMieux is an attorney and public servant who served as Florida’s 34th United States Senator from 2009 to 2011. He is Chairman of Gunster and founder of Palm Beach Atlantic University’s LeMieux Center for Public Policy.

George S. LeMieux

Chairman of the Board of Directors, Gunster

hopco.com

Dr. Wael Barsoum is a visionary orthopedic surgeon and healthcare executive with over 20 years of experience leading growth and transformation. As President and Chief Transformation Officer at HOPCo, he advances value-based care and musculoskeletal outcomes. He previously served as CEO and President of Cleveland Clinic Florida, driving significant systemwide expansion.

Wael Barsoum President and Chief Transformation Officer, Healthcare Outcomes Performance Company

rapiddevicetranslation.org

Homer Quintana accelerates medical device innovation from concept to clinic. By leveraging centralized clinical resources and strategic oversight, he streamlines the path through preclinical and clinical trials. A Master in Clinical Translation Management pioneer and advisor, Homer empowers partners to navigate complex development hurdles and scale within the global medtech ecosystem.

Homer Quintana Director, Center for Rapid Device Translation, Houston Methodist

igenticai.com

Dr. Zahra Timsah is a global business and technology leader, founder, and CEO with deep expertise in AI, data, digital transformation, and regulatory innovation. She has supported major enterprises worldwide, cofounded multiple ventures, and now leads i-GENTIC in advancing governance and compliance for highly regulated industries.

Zahra Timsah

Chief Executive Officer, i-GENTIC AI

immortabio.com

Boris Reznik, PhD, is Chairman & CEO of Immorta Bio, advancing a unique dual-platform strategy to restore youthful biology. SenoVaxâ is a firstin-class senolytic immunotherapy, while StemCellRevivifyâ is a nextgeneration regenerative platform. A serial entrepreneur, he has led Inc. 500 companies, IPOs, and M&As, and contributed to dozens of NDA/BLA programs.

Boris Reznik Chairman & CEO, Immorta Bio Inc.

medaxiom.com

A commercialization leader and MedTech investor, Joe Sasson is co-founder of the HeartX accelerator and has helped bring 100+ companies or products to market. Drawing on expertise in marketing, sales, strategy, and operations, he drives growth that delivers patient impact, reduces healthcare costs, and produces successful exits.

Joe Sasson

Chief Commercial Officer and EVP, Ventures, MedAxiom

matrixone.health

Alex Condon is COO of Matrix Connect, part of Matrix One, a portfolio of software platforms designed to support the development and management of modern medical technologies. He works with medical device companies to enable secure cloud connectivity, accelerate innovation, and bring connected devices and digital health solutions to market.

Alex Condon COO, Matrix One

mpfi.org

Dr. Paul Evans is scientific Ambassador for MPFI. Paul fosters collaborations across academia, business, and government to support life sciences innovation. He plays a key role in diversifying the Institute’s funding portfolio and building local science ecosystems while promoting cuttingedge research and partnerships.

Paul Evans

Associate Vice President of External Affairs, Max Planck Florida Institute for Neuroscience

musc.edu

Bob is a healthcare executive with 30+ years of leadership across services, IT, devices, venture capital, and startups. Managing Director of 1824 Health Ventures Fund and South Carolina Health Innovation Fund at MUSC.

Robert L. Crutchfield Managing Director, 1824 Health Ventures & SC Health innovations Fund, Medical University of South Carolina

medmarc.com

Lynn Carney has extensive experience in the insurance industry. She joined Medmarc in 2007, starting as the Manager of the Marketing and Business Development Department and later advancing to the Director of Agency and Alliances. She has spent the last 18 years advising life science startups on their risk management and insurance products.

Lynn Carney Director, Agency and Alliances, Medmarc

americasfrontier.org

Karl Mehta is a technology entrepreneur, investor and author with over 30 years of experience. He has founded and exited multiple companies, served as a Presidential Innovation Fellow, and shares insights on technology, AI and business.

Karl Mehta Partner, Mehta Family Offiice

neopredics.com

Thorsten Waloschek is CEO of NeoPredics, a digital health company developing predictive analytics for maternal and neonatal care. With over 25 years in MedTech leadership, including roles at Dräger and Natus, he is a recognized expert in neonatology, innovation, and global healthcare commercialization.

Thorsten Waloschek CEO, NeoPredics

pacemate.com

Tripp is the founder and former CEO of Pacemate, the nation’s leading remote cardiac monitoring platform. After bootstrapping the company for six years, he raised $150M, acquired Paceart from Medtronic, and scaled to $50M in revenue and 1M+ patients. Backed by Lead Edge Capital, he now serves as the Chairman.

Tripp Higgins Founder, Chairman, Pacemate

pegasuspark.com

Dr. David E. Snow is Executive Director of Pegasus Park and an innovation executive with 15+ years building venture pipelines, de-risking technologies, and scaling high-growth ecosystems. He has led commercialization and early-stage investment strategies across academia and industry and is a Certified Licensing Professional, Patent Agent, and Ph.D. chemist.

David Snow Executive Director, Pegasus Park

podymos.com

Claudia Holy is the Founder and CEO of Podymos, a specialist marketing agency dedicated exclusively to medical devices. Claudia is a certified Endless Customers coach with 20+ years of commercial MedTech experience. Claudia and her team help device companies build content-led sales and marketing channels that speed up device adoption.

Claudia Holy Founder and CEO, Podymos

plsp.pro

Addie is a medtech founder, executive and investor with over two decades of experience. She founded Cardan Robotics, later acquired by Stryker, and has led global robotics R&D at Johnson & Johnson while advising international venture firms.

Addie Harris Partner, Precision Life Science Partners

projectusconsulting.com

Founder of Projectus Medtech’s only dedicated search firm with therapy specific specialist teams based across the US, EMEA and APAC

Tim Lawrie

Founder and CEO, Projectus

ResearchParkFAU.com

Andrew Duffell, MBA, has led the Research Park at Florida Atlantic University since 2011, transforming it into South Florida’s premier tech and entrepreneurial hub. A champion of regional economic development, he has earned multiple leadership awards and holds degrees from the University of Aberdeen and Florida Atlantic University.

Andrew S. Duffell

President, Research Park at Florida Atlantic University

sugativentures.com

Rachna is an outcomes-focused leader with experience across venture capital, healthcare marketing and technology management. She has led major initiatives for global firms, managed a $350 million P&L, and holds extensive board and governance roles.

Rachna Dayal

Managing Partner, Sugati Ventures

svhealthinvestors.com

Greg Madden is Managing Partner at SV Health Investors, a multi-strategy healthcare firm with offices in Boston and London. He joined SV in 2002 and leads the medical technology and services practice, focusing on growth equity and buyouts. He oversees financing, strategy, operations, and acquisitions across the firm’s portfolio companies.

Greg Madden

Managing Partner, SV Health Investors

serialstagevp.com

Eric C. Ulchaker is an entrepreneur and venture investor with experience in pre-seed and seed-stage investing. He managed Notre Dame’s $23M Pit Road Fund and supported the launch of the 1842 Fund with High Alpha Innovation. Eric focuses on MedTech, BioTech, and HealthTech and holds degrees from Ohio State, Notre Dame, and Case Western Reserve.

Eric C. Ulchaker, MS, MFin Managing Partner, Serial Stage Venture Partners

tdsecurities.com/ca/en/health-care

Cale Garverick is a Managing Director at TD Cowen with over a decade of experience in healthcare investment banking. He has completed more than 150 transactions and began his career at OrbiMed and Wedbush PacGrow.

Cale Garverick

Managing Director, TD Cowen

tramwayventures.com

Chris Japp is a Managing Partner at Tramway Ventures, a venture capital firm with offices in Albuquerque and Santa Fe New Mexico that is focused on early stage medtech and biotech investments. Prior to joining Tramway, Chris was a seasoned c-suite medtech executive working at both large multinationals as well as mid size companies at various locations around the world.

Chris Japp Managing Partner, Tramway Ventures

umiamihealth.org

Dipen J. Parekh, M.D. is a globally recognized healthcare leader, urologic oncologist, robotic surgeon, and innovator. He serves as CEO of the University of Miami Health System, and EVP for Health Affairs at University of Miami. Founding Director of the Desai Sethi Urology Institute and holds the Victor A. Politano Endowed Chair and Magnier family Endowed Chair in Urology.

Dr. Dipen J Parekh CEO of UHealth, University of Miami Health System

vitvio.com

Dr David Rawaf is a surgeon, researcher, and health-technology innovator specializing in AI-driven surgical systems. He leads clinical strategy and partnerships at VitVio, developing computer-vision technology to digitize operating rooms. With academic and research roles linked to Imperial College London and global health organizations, he focuses on improving surgical efficiency and patient outcomes through intelligent healthcare technology.

Dr David L Rawaf CMO/Clinical Director, VitVio

Media Partners

European Hospital and Healthcare Management, a prominent B2B global print publication, serves as the authoritative guide for healthcare professionals. Committed to delivering in-depth insights, our platform provides a comprehensive view of healthcare trends, management strategies, and innovative solutions, empowering healthcare leaders to navigate complexities and drive positive change.

ochre-media.com

BioPartner UK is an independent trade organisation promoting international partnerships, trade, and investment with UK life science companies. Collaborating with public and private sectors, it organises events, projects, and missions, leveraging technology partners to connect global stakeholders and efficiently support the UK life science sector with innovative solutions.

biopartner.co.uk

DigitalHealth.London connects NHS staff, digital health companies, and academics to improve NHS and social care through technology. Delivered by the Health Innovation Network, it provides mentoring, education, networking, and partnership opportunities. Supported by government and partners, it empowers digital health leaders to tackle challenges and drive innovation across London’s healthcare system.

digitalhealth.london

ArabMedicare.com is a comprehensive digital platform dedicated to healthcare professionals in the Middle East and North Africa (MENA) region. Established over 25 years ago, it offers medical news, job listings, country-specific healthcare profiles, and resources on medical devices, health insurance, and environmental health.

arabmedicare.com

CAA is an integrated media platform that produces in-depth business intelligence through its annual print and digital economic reviews, high-impact conferences and events and top-level, executive interviews.

capitalanalyticsassociates.com

The Distretto Biomedicale Mirandolese in northern Modena, Italy, is Europe’s leading biomedical cluster and third largest globally. Hosting over 300 companies, it specializes in medical devices and disposables. Renowned for innovation, export strength, and advanced manufacturing, the district plays a pivotal role in healthcare production and supports the global medical technology industry.

distrettobiomedicale.it

Esimatic is a global eSIM provider offering prepaid mobile data plans for travelers in over 200 countries. Through its user-friendly app, users can access high-speed 4G/LTE and 5G networks without physical SIM cards, enjoying flexible data packages ranging from 1GB to unlimited options. Ideal for tourists, remote workers, and digital nomads, Esimatic provides instant activation, no ID verification, and eco-friendly connectivity solutions.

esimatic.co

HealthTechAsia (HTA) is a B2B intelligence and advisory platform covering digital health, healthtech, and health AI policy across Asia-Pacific and the Middle East. HTA publishes independent analysis, interviews, and commentary for professionals shaping the sector, and works with organisations navigating market entry, regulatory complexity, and stakeholder engagement across the region.

healthtechasia.co

Medgate Today is a leading international MedTech and healthcare magazine headquartered in India. It connects innovators with the medical community, offering in-depth reporting through its monthly print and digital editions. The publication also hosts the prestigious MT India Healthcare Awards to recognise excellence in the sector. medgatetoday.com

Health Wildcatters, founded in 2013, is a Dallas-Fort Worthbased health innovation hub. Its portfolio includes 130 startups that have raised over $350 million. The accelerator selects 8–12 startups annually for a ten-week program, offering seed investment, in-kind perks, and access to a robust network of 200+ healthcare and industry mentors.

healthwildcatters.com

Medarabia is the Middle East’s largest healthcare network, founded to empower the industry by enabling users to share experiences and post reviews about doctors, clinics, hospitals, and other service providers. It bridges the communication gap between patients and practitioners, helping users make informed healthcare decisions.

m.edarabia.com

MedTech Europe promotes innovative medical technology across Europe, supporting sustainable healthcare and valuebased solutions. Formed in 2012 from EDMA and Eucomed, it engages policymakers, drives research, and organizes events to highlight medical technology’s impact. By fostering collaboration and innovation, MedTech Europe ensures healthcare systems meet Europe’s evolving needs effectively.

medtecheurope.org

MedTech Spectrum is an online media platform dedicated to medical technology and healthcare innovation. It publishes news, analysis, interviews, events and job listings covering medical devices, diagnostics, digital health and industry trends, keeping professionals and enthusiasts informed about breakthroughs, regulatory updates and the evolving MedTech landscape.

medtechspectrum.com

SEHTA (Science and Engineering Health Technologies Alliance) is a UK-based, not-for-profit health technology network founded in 2005 that supports innovators, SMEs, clinicians, care providers and academics. It accelerates health tech innovation from concept to commercialisation with business support, training, events and networking, including the International MedTech Expo & Conference. SEHTA’s mission is to improve healthcare outcomes and grow economic impact through collaboration and expert guidance.

sehta.co.uk

StartupNews.fyi is India’s leading news and technology media company, focusing on startups in India and global stories. With over 2 million enthusiasts, it offers curated news, funding updates, and event coverage. The platform also facilitates international startup delegations and partnerships, connecting startups and investors worldwide.

startupnews.fyi

One HealthTech is a global community promoting diversity and inclusion in health innovation. Supporting women and underrepresented groups, OHT provides mentorship, education, and networking across digital health. With hubs in the UK, Europe, and Australia, it champions leadership, collaboration, and participation in healthtech events and initiatives.

onehealthtech.com

Startups Magazine, launched in April 2018, is a bi-monthly platform championing tech startups. It offers expert content, digital issues, event access, and startup features, while connecting a passionate community of founders, investors, and innovators. It also curates industry events, podcasts, and practical guidance for entrepreneurial success.

startupsmagazine.co.uk

The Business Year is a global media group offering in-depth insights into dynamic markets. For over a decade, it has conducted interviews with top decision-makers across the Middle East, Latin America, Central and Southeast Asia, Africa, and Europe, providing valuable information to investors, businesses, and governments worldwide.

thebusinessyear.com

The Device Files, launched in July 2025, is a must-read digital publication for CEOs, investors, and founders in MedTech, DTx, and Wearables. It offers strategic insights on product development, commercialization, and operations, helping readers gain a competitive edge, make smarter investment decisions, and navigate regulatory challenges for faster market entry.

blythekarow.substack.com

World Business Outlook is a Singapore-based business magazine delivering global financial news, market insights, and industry views across sectors. Its pages feature innovative companies and showcase opinions from top business leaders, providing readers with in-depth coverage of trends, market developments, and the latest business strategies worldwide. worldbusinessoutlook.com

Medical Buyer is a leading monthly magazine and web portal in India, connecting medical equipment buyers and vendors. It provides reliable information for purchase decisions, vendor promotion, and customer lead generation. Published by ADI Media, it focuses on unbiased reporting, ensuring relevant business information for healthcare professionals.

medicalbuyer.co.in

ZEX PR WIRE® is an automated press release distribution platform, syndicating content to over 500 global media outlets. Designed for PR teams and agencies, it allows users to conduct and manage campaigns with zero mail trails and mediators. The platform delivers press releases within 72 hours, ensuring fast, efficient service.

zexprwire.com

MedTech World Team

Meet the squad

Dr. Dylan Attard

CEO

MedTech

World

Yulia Yurevich Head of Client Relations & Partnerships

Shara Layton Head of Marketing

Dr. Miguel Fenech

Business Development Manager

Dylan strongly believes in collaborative efforts to enhance the healthcare system. He is dedicated to making MedTech World the epicenter of investment and progress. He aims to create a platform for meaningful discussions, fostering innovation and connections for entrepreneurs to scale their solutions.

As an entrepreneurial enthusiast in the MedTech industry, Yulia specialises in connecting global innovators, investors, and healthcare professionals to accelerate healthcare transformation also creating strategic opportunities for emerging ventures in the MedTech ecosystem.

Shara believes working in the MedTech industry is not just a profession but a purpose. She finds it incredibly fulfilling to contribute to groundbreaking innovations that are transforming global healthcare and improving lives around the world.

Miguel is a medical doctor with extensive clinical experience across London and the UK. He has a keen interest in the safety, regulation, and ethical integration of AI-driven healthcare solutions in patient care and is a certified Clinical Safety Officer with NHS England.

MedTech World Team

Meet the squad

Anastasia Coleiro

Global Account Manager

Wara Samar Senior Content Writer

Rusudan

Khotivari

Media Partnerships

Coordinator

Business graduate, Anastasia finds purpose in contributing to the MedTech industry, connecting people, building meaningful relationships, and delivering seamless, highquality experiences through authenticity, organisation, and a people-first approach.

creating meaningful conversations across the MedTech industry.

partnerships in the healthcare technology sector. Ready to connect with driven individuals who share a passion for innovation and growth.

A postgraduate in Biotechnology, Wara has extensive experience in scientific editing and content writing. She covers impactful medical technology stories with a keen editorial eye for clarity and detail.

Communications professional with 7+ years of experience in UN agencies, NGOs, and the private sector. Specialized in strategic communications, media relations and stakeholder coordination, Rusudan is passionate about MedTech and Public Health.

D evel o pme n t

C loud & Apps

• Android/iOS

• Windows/MacOS/Linux

• Web Apps

Scan here for a free 30 minute

Initial Consultation

• Gap Analysis

• Secure Soft ware Development Lifecycle

• Cybersecurit y Risk Assessment

• Device Drivers A cce l e ra ti n g M e d Tec h So ft w a re

• 3rd Party Integrations

• Data Storage

• Cloud Infrastructure

Cybersecurit y & Regula tor

y

• Soft ware Regula tor y Review

• Vulnerabilit y Assessment

• Verifica tion & Valida tion Testing

• ML/AI

• Computer Vision

• Model Training

• Workspace Setup

Da ta Collection & Ana ly tics Embedded

• Data Collection & Analytics

• Data Collection & Labelling

• Algorithm Development

Systems

• FPGA

• SoC/SoM

• Single Board Computer

• PLC/HMI

• Firmware